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ABSTRACT OF THE DISSERTATION 
AUTO-ANTIGENIC PROPERTIES OF THE SPLICEOSOME AS A MOLECULAR 
TOOL FOR DIAGNOSING SYSTEMIC LUPUS ERYTHEMATOSUS AND MIXED 
CONNECTIVE TISSUE DISEASE PATIENTS 
by 
Annia Mesa 
Florida International University, 2014 
Miami, Florida 
Professor DeEtta K. Mills, Major Professor 
Systemic Lupus Erythematosus (SLE) and Mixed Connective Tissue Disease (MCTD) 
are chronic, autoimmune disorders that target overlapping autoantigens and exhibit 
similar clinical manifestations. Despite 40 years of research, a reliable biomarker capable 
of diagnosing these syndromes has yet to be identified. Previous studies have confirmed 
that components of the U1 small nuclear ribonucleoprotein complex (U1 snRNP) such as 
U1A are 1000 fold more autoantigenic than any other nuclear component in SLE patients. 
Based on these findings, I hypothesize that models derived from the U1 snRNP 
autoantigenic properties could distinguish SLE from MCTD patients. To test this 
hypothesis, 30 peptides corresponding to protein regions of the U1 snRNP were tested in 
triplicates by indirect ELISA in sera from SLE or MCTD subjects. In addition laboratory 
tests and clinical manifestations data from these patients were included and analyzed in 
this investigation. Statistical classification methods as well as bioinformatics pattern 
recognition strategy were employed to determine which combination, if any, of all the 
variables included in this study provide the best segregation power for SLE and MCTD. 
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The results confirmed that the IgM reactivity for U1 snRNP and U1A have the power to 
significantly distinguish SLE from MTCD patients as well as identify kidney and lung 
malfunctions for these subjects (p ≤ 0.05). Furthermore, the data analysis revealed eight 
novel classification rules for the segregation of SLE and MCTD which are a better 
classification tool than any of the currently available methods (p ≤ 0.05). Consequently, 
the results derived from this study support that SLE and MCTD are indeed separate 
disorders and pioneer the description of eight novel classification criteria capable of 
significantly discerning between SLE and MCTD patients (p ≤ 0.05).  
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I. INTRODUCTION 
 Autoimmune diseases develop when the immune system stops recognizing self 
antigens and produces aberrant antibodies capable of developing equally over-reactive 
responses to self as well as non-self antigens (Carroll, 2004). In general, individuals 
diagnosed with these syndromes represent a heterogeneous population characterized by a 
broad number of clinical manifestations that have unpredictable courses and often cannot 
be associated with a unique autoimmune illness (Konforte et al., 2012). It is without 
doubt that early and accurate recognition of these diseases could dictate the patient’s 
treatment which in turn has the potential to improve the prognosis as well as reduce the 
financial burden to the ill subject and family (Bodolay et al., 2007). Nevertheless, the 
lack of recognition and categorization methods for autoimmune syndromes exhibiting 
clinical and molecular features common in other well characterized autoimmune illnesses 
has hampered diagnosis. As result, patients exhibiting characteristic overlapping clinical 
manifestations observed in different autoimmune syndromes are often misdiagnosed and 
go through years of clinical investigations and laboratory tests before obtaining the 
accurate diagnosis (Adsay et al., 2005; Simao, 2010; Niţescu  et al., 2011; Quinkler, 
2012; Bertsias et al., 2013; Pena et al., 2013). 
 Mixed Connective Tissue Disease (MCTD) is one of the most commonly known 
syndromes showing overlapping characteristics with other autoimmune disorders (Rebora 
and Parodi, 1990; Aringer et al., 2005; Swanton and Isenberg, 2005; Nowicka-Sauer et 
al., 2012). Sharp et al. (1972) initially described MCTD as a systemic autoimmune 
disease characterized by elevated antibodies directed to subunits of the U1 small nuclear 
ribonucloprotein particle (snRNP). Since then, diverse research groups defined it as a 
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non-specific autoimmune syndrome with clinical and molecular features observed in 
others syndromes such as Systemic Lupus Erythematosus (SLE), Systemic Sclerosis 
(SS), Rheumatoid Arthritis (RA) and Polymyositis (PM) (Mukerji and Hardin, 1993; 
Egner, 2000; Haustein, 2005). The initial, but not always reliable, description of MCTD 
as a benign disease that transforms into other well known autoimmune disorders has 
limited its recognition during the study of SLE and other cohorts of autoimmune patients 
(Sharp et al., 1972; Tan et al., 1982; Hochberg et al., 1997; Lundberg, 2005; Petri et al., 
2012; Shi et al., 2012). Recent studies have shown lung disease seems to be specifically 
associated with MCTD but not SLE patients (Shirai et al., 2012; Watanabe et al., 2012; 
Gunnarsson et al., 2013). By contrast, renal disorders have long been a characteristic 
prevalent in SLE but not the MCTD population (Everett and Harrell, 1956; Natali et al., 
1972; Cavagna et al., 2013; Lin et al., 2013). The fact that independent studies have 
described that SLE and MCTD patients are associated with malfunction of different 
organs highlights the relevance of the recognition of MCTD concept as a clinical tool to 
identify patients that could develop lung disease as oppose to kidney malfunction, for 
example. Given that four different criteria sets currently coexist to identify MCTD 
patients illustrates the significant challenges in uncovering clinical symptoms and/or 
biomarkers that could be specifically associated with this autoimmune syndrome (Sharp, 
1987; Kasukawa et al, 1988; Kahn et al., 1991; Amigues et al., 1996). 
 During the past six decades, extensive studies have provided evidence to support 
the following: first, MCTD exhibited a considerable number of overlapping features with 
SLE making virtually impossible the segregation of some patients using currently 
available classification criteria sets (Sharp et al., 1972; Tan et al., 1982; Amigues et al., 
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1996; Hochberg et al., 1997; Lundberg, 2005; Petri et al., 2012; Shi et al., 2012). Second, 
the concept of MCTD has clinical relevance since malfunction of vital organs has been 
reported to be prevalent in this syndrome when compared to SLE, for example (Everett 
and Harrell, 1956; Natali et al., 1972; Shirai et al., 2012; Watanabe et al., 2012; 
Gunnarsson et al., 2013). Third, new classification rules with significant power to 
distinguish between SLE and MCTD patients need to be developed given that available 
classification criteria sets were designed to identify either SLE or MCTD subjects but not 
to segregate between these two autoimmune disorders (Sharp, 1987; Kasukawa et al, 
1988; Kahn et al., 1991; Amigues et al., 1996; Hochberg et al., 1997; Petri et al., 2012). 
Prompted by the clinical need for developing accurate methods to segregate between SLE 
and MCTD patients, the present study explores auto-antigenic properties of the 
spliceosome; a potential novel molecular tool for the discrimination of these two 
autoimmune syndromes.                             
 The spliceosome is a macromolecule composed of five distinguished RNA and 
protein complexes known as U1 small nuclear ribonucleoprotein (U1 snRNP), U2 
snRNP, U4 snRNP, U5 snRNP and U6 snRNP (Moore et al., 1993). All these snRNP 
composites are arranged around the nascent pre-mRNA to remove introns and link exons 
through the splicing reaction producing a final mature mRNA (Staley and Guthrie, 1998). 
Earlier reports have confirmed the auto-antigenic properties of U1 snRNP in SLE and 
MCTD patients. The U1 snRNP is the first spliceosomal subunit binding the pre-mRNA 
and is composed of three specific U1 snRNP proteins (U1-70K, U1Ap and U1C) and 
seven Smith (Sm) proteins (Pomeranz Krummel et al., 2009). Specifically, MCTD 
subjects show prevalence of autoimmune response to U1 snRNP specific proteins 
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(snRNP) while SLE individuals have a predominance response to Sm proteins (Luyckx et 
al., 2005). Interestingly, the majority of previous analyses have focused on the auto-
antigenic properties of U1-70K and Sm proteins but not on U1A and U1C (McClain et 
al., 2004; Luyckx et al., 2005). Likewise, the immunoglobulin G (IgG) immune response 
for these and other nuclear antigens have been extensively documented in SLE and 
MCTD patients while the potential role of other immunoglobulins (IgM, IgD, IgE and 
IgA) has been limited (Zhang et al., 1995; Vlachoyiannopoulos et al., 1996; Witte et al., 
1998; Palafox Sanchez et al; 2009).  
 The present study will apply novel classification rules specifically designed for 
SLE and MCTD discrimination by exploring the IgM response for 15 U1A and 15 
additional U1 snRNP peptides, as well as analyzing the frequency and correlations of 183 
clinical symptoms and biomarkers recorded in patients with these autoimmune 
syndromes. The data analyses confirmed previous findings that the immune response for 
U1A and U1 snRNP peptides mature from IgM to IgG in MCTD patients while SLE 
subjects appear to retain IgM responses for these autoantigens. In addition, the results 
revealed that models derived from the IgM reactivity for U1 snRNP and IgM anti-U1A 
titers have the power to significantly segregate between SLE and MTCD patients as well 
as identify kidney and lung malfunctions in subjects diagnosed with any of these two 
illnesses (p ≤ 0.05), respectively. Furthermore, eight novel classification rules for the 
segregation of SLE and MCTD were described and showed better classification power 
than any of the currently available methods (p ≤ 0.05). Consequently, the results derived 
from this study provide evidence to support the notion that SLE and MCTD are indeed 
separate disorders while pioneer the description of eight novel classification criteria sets 
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capable of discerning between SLE and MCTD patients (p ≤ 0.05). Recognizing that 
validation of these findings is required, the data described have the potential to improve 
the accurate clinical diagnosis of SLE and MCTD which in turn could increase the 
patient’s prognosis and life quality.                     
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II. CHAPTER 1 
 
Uncovering the IgM autoimmune response for U1Ap  
in patients diagnosed with SLE or MCTD  
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Introduction 
 The small nuclear ribonucleoprotein (snRNP) A (referred to here as “U1Ap”), in 
combination with U1-70K and U1C, is a specific U1 RNP polypeptide that, along with 
the U1-RNA and Sm proteins, forms an active U1 snRNP complex. The complex, in turn, 
plays an essential role in pre-mRNA processing as a functional unit of the spliceosome 
(Moore and Sharp, 1993). The spliceosomal composite is formed of two RNA 
recognition motifs (RRM) located at the N- and C-terminal of the U1Ap and has been 
reported to be conserved across the Eukaryote domain (Scherly et al., 1989; Chen et al., 
2007; Somarelli et al., 2010). The N-terminal RRM domain (RRM1) of U1Ap has been 
extensively studied and has been shown to be necessary and sufficient to bind U1-RNA 
via its stem loop II and facilitate the splicing process (Scherly et al., 1989, Jessen et al., 
1991, Somarelli et al., 2010). By contrast, little is known about the potential function of 
the U1Ap C-terminal RRM domain (RRM2) despite similar characteristics to other RNA 
binding domains including U1Ap RRM1 (Scherly et al., 1989, Tang and Rosbash, 1996). 
The RRM2 of U1Ap exhibits unusual RNA binding properties since it does not bind to 
U1, U2 or U5 stem loops or interact with random RNA sequences (Lu and Hall, 1995).  
 Autoimmune responses to U1 snRNP specific proteins, including U1Ap, have 
been described in patients diagnosed with Systemic Lupus Erythematosus (SLE) and 
Mixed Connective Tissue Disease (MCTD) (de Wildt et al., 1997; Faig and Lutz , 2003; 
McClain et al., 2004; Sato et al., 2010). In some patient cohorts, anti-U1Ap responses 
have been reported to be the first anti-U1-snRNP to develop (McClain et al., 2004).  
Major organ involvement, including lung and kidney, are common in these individuals 
(Gutsche et al., 2012; Braun-Moscovici et al., 2013). Though MCTD was described as a 
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separate disorder (Sharp et al., 1972), there is much controversy regarding its 
independent nature because of the great number of overlapping auto-antigens and clinical 
manifestations shared with SLE (Rebora and Parodi, 1990; Swanton and Isenberg, 2005; 
Nowicka-Sauer et al., 2012). Nevertheless, there are auto-antigens and clinical symptoms 
that are more frequently exhibited in one disease group than the other. For example, SLE 
patients show elevated immunoglobulin G (IgG) autoimmune responses to Sm proteins 
while those with the autoimmune response directed to snRNP subunits are frequently 
MCTD individuals (Luyckx et al., 2005). Clinically, kidney damage is more frequent in 
SLE while lung malfunction is often observed in MCTD patients (De Clerck et al., 1989; 
Sawai et al 1994; Yoshida et al., 1994; Watanabe et al., 2012). Previous studies have 
described elevated IgG autoimmune response to U1Ap fragments in both SLE and 
MCTD patients (Sato et al., 2010). In addition, Vlachoyiannopoulos et al. (1996) reported 
that SLE but not MCTD patients showed a predominant immunoglobulin M (IgM) 
response to snRNP subunits, including U1Ap. Furthermore, a recent study revealed that 
U1Ap antigenicity against IgM could aid in the differentiation between these two 
autoimmune disorders (Mesa et al., 2013).  
  The aim of the present study is to examine the IgM responses to U1Ap as a 
molecular indicator to assess differences between SLE and MCTD, and to uncover 
potential relevance of anti-U1Ap IgM reactivity in predicting organ targeting. To 
accomplish the goal, a total of 17 U1Ap peptides encompassing most of the protein’s 
sequence were monitored for their IgM antigenicity in sera from SLE and MCTD patients 
with or without kidney and/or lung involvement. The results support previous findings 
that SLE but not MCTD patients have prevalent IgM responses to U1Ap peptides 
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(Vlachoyiannopoulos et al., 1996, Mesa et al., 2013). Furthermore, IgM reactivity to 
specific U1Ap fragments has potential to identify patients with kidney and lung 
involvement with an accuracy of 72% and 71%, respectively (p ≤ 0.005). Consequently, 
this investigation provides evidence to support that the IgM response to U1Ap peptides 
could be employed as a predictive blood marker for kidney and lung damage in patients 
diagnosed with either SLE or MCTD while contributing additional molecular evidence to 
support the separate etiology of these autoimmune syndromes.    
       
Materials and Methods  
Patients recruitment 
 In this study, SLE (n = 56) and MCTD (n = 26) individuals presenting in either 
outpatient or inpatient settings to the Division of Rheumatology at the University of 
Miami Miller School of Medicine, consented to participate in research studies following 
IRB-approved protocols between 2005 and 2010. Healthy individuals (n = 10) also 
consenting to participate following IRB-approved guidelines were included as negative 
controls. The American College of Rheumatology (ACR) classification criteria 
(Hochberg et al., 1997) and the Alarcon Segovia criteria (Amigues et al., 1996) were used 
to classify patients as having SLE and MCTD, respectively. In cases where both criteria 
sets were satisfied, patient diagnoses were determined by the chart-documented 
diagnoses of their clinical rheumatologists.  All SLE and MCTD individuals included in 
this investigation represent well characterized patients and have been subjects of previous 
studies (Maldonado et al., 2006; Perkins et al., 2008; Somarelli et al., 2011, Mesa et al., 
2013).       
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Medical records selection  
 Kidney involvement was defined following the American College of 
Rheumatology SLE Classification Criteria’s renal criterion (Hochberg et al., 1997) and/or 
renal biopsy. Sufficient information was available to make a determination in 70 of the 
82 study patients.  Kidney involvement was present in 22 patients (19 SLE and 3 
MCTD), and was absent in 48 patients (26 SLE and 22 MCTD). Lung disease was 
designated to be present if pulmonary fibrosis was confirmed by chest X-ray or CT-scan, 
or if pulmonary artery pressure by right heart catheterization or right ventricular systolic 
pressure estimated by echocardiography meter exceeded 40 mmHg. Sufficient 
information existed to make a determination about lung involvement in 52 patients, of 
whom 26 patients had lung involvement (SLE = 18 and MCTD = 8) and 26 did not have 
lung involvement (SLE = 20 and MCTD = 6). All the medical records were obtained 
following the IRB protocols from University of Miami (IRB numbers: 20030724 and 
20040286) and Florida International University (IRB number: 040308-00).         
 
Selection and synthesis of U1Ap peptides 
 Auto-antigenic U1Ap peptides known to elicit an IgG autoimmune reaction in 
SLE patients were obtained from literature review to be tested for IgM antigenicity 
(Barakat et al., 1991; Arbuckle et al., 1998; Talken et al., 2001; Poole et al., 2009; 
Somarelli et al., 2011). In addition, amino acid sequences corresponding to each of the 
two RNA recognition motifs (RRMs) were included as peptides (P4 and P14, Table 1). 
All peptides were commercially synthesized by BioMatik Corporation (Wilmington, DE, 
USA) and purified by high performance liquid chromatography to ≥ 90% purity.    
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Assessing IgM autoimmune response for U1A protein peptides  
Whole blood from SLE (67 samples from 56 patients), MCTD (29 samples from 
26 patients) and healthy (11 samples from 10 persons) individuals were obtained at the 
moment of the recruitment and subsequent follow up visits, when applicable. Supernatant 
serum from each patient was diluted 1:100 in phosphate buffered saline (1X PBS) 
containing 10 mg/ml bovine serum albumin (BSA) and 0.5 mM phenylmethylsulphonyl 
fluoride (PMSF) and subsequently stored at -80°C until tested. Diluted sample sera from 
SLE, MCTD and healthy individuals were used to determine IgM reactivity for U1Ap 
peptides via indirect-ELISA as previously described (Somarelli et al., 2011, Mesa et al., 
2013). Goat anti-human IgM horseradish peroxidase conjugated second antibody 
(Southern Biotech, Birmingham, AL, USA) used at 1:2000 in BSA/PBS containing 
0.05% Tween-20 (BSA/PBS-T). All ELISAs were performed in triplicate. Each ELISA 
plate contained no peptide, no serum, no conjugate and no substrate controls. The optical 
density (OD) value of the IgM anti-U1Ap titers in each patient was normalized by the 
average IgM anti-U1Ap reactivity in the healthy group per peptide examined and 
expressed as OD% following established methods (Muñoz-Paredes et al. 1999).     
  
Generating and evaluating the U1Ap three-dimensional structure 
 A three-dimensional (3D) structural model of the full-length U1Ap (amino acids 
1-282) was required to analyze the IgM anti-U1Ap titers given that currently the nuclear 
magnetic resonance (NMR) structure for human U1Ap only includes residues 2 to 102 
(Protein Data Bank (PDB) ID number: 1DZ5).  To generate a complete U1Ap 3D 
structure, the U1Ap linear sequence was retrieved from the National Center for 
25 
 
Biotechnology Information (NCBI) protein data bank (accession number: P09012) and 
submitted to the I-TASSER server for protein structure and function prediction 
(http://zhanglab.ccmb.med.umich.edu/I-TASSER/) (Roy et al., 2010 and 2012). A total of 
five models were generated for U1Ap with confidence scores (C-score) ranging from -
2.19 to -3.98. Each of the U1Ap 3D models was superimposed on the U1Ap NMR 3D 
structure (PDB ID: 1DZ5 containing 12 ensemble structures) using PyMOL (version 
1.30) to obtain the most accurate structure possible. The best U1Ap model was selected 
by finding the highest ratio of overlaid atoms to root mean square deviation (RMSD) 
during super-positioning on each of the NMR structures in the ensemble. The I-TASSER 
model 2 paired with ensemble structure 12 given that the assemble yielded the highest 
ratio (565:1.679=318.0; detailed protocol for generating and evaluating U1Ap 3D models 
is included in Appendix 1).    
 
Mapping IgM response onto U1A protein 3D structure in SLE and MCTD patients 
The observed IgM responses for U1Ap peptides in SLE and MCTD patients were 
mapped independently onto the U1Ap 3D model. To construct the IgM reactivity 
gradient for each peptide, the average value of the healthy group was adjusted to a 
baseline of 0.5. Subsequently, the average IgM reactivity recorded in each of the SLE and 
MCTD groups was expressed as a proportion relative to that baseline. Reactivity lower or 
higher than the healthy patient averages per peptides resulted in proportional values 
below or above 0.5, respectively. On the basis of the proportional value, each peptide was 
mapped on a heat map with the scale ranging from blue for the lowest antigenicity, to 
green, yellow, and finally red for the highest antigenicity.      
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Statistical analysis 
 Significant differences in the average peptide antigenicity against IgM, in SLE 
and MCTD patients were assessed by independent sample t-test. Correlation analyses 
were performed to verify the IgM responses for U1Ap peptides were not correlated to 
peptide size (p ≤ 0.05). A Chi-square test was employed to compare clinical and 
laboratory categorical variables between SLE and MCTD patients. Spearman’s 
correlation was employed to assess the association between IgM anti-U1Ap titers and 
kidney or lung involvement. Binomial Logistic Regression (BLR) was used to assess 
which combination of IgM reactivity for U1Ap peptides enhanced the discrimination 
between patients presenting with kidney or lung involvement versus those lacking these 
manifestations. Peptides that were found to be not significant in BLR analysis were not 
included in subsequent tests. Receiving Operating Characteristics (ROC) curves were 
used to confirm results obtained by BLR and determine the cut off values to ensure the 
best sensitivity and specificity for kidney and lung models which were 0.5 and 0.6, 
respectively. All the statistical analyses were performed using PASW statistical Data 
Editor, version 18, with p ≤ 0.05 set as the standard for statistical inference for all the 
tests executed.  
 
Results  
U1Ap peptides showed contrasting IgM antigenicity in SLE and MCTD patients 
 Indirect ELISAs were employed to assess IgM responses for U1Ap peptides in 
sera from SLE, MCTD and healthy individuals. In general, SLE patients exhibited higher 
IgM anti-U1Ap titers when compared to the healthy individuals (P1-P11 and P13, Figure 
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1). By contrast, except for P5, P8 and P9, MCTD patients had lower IgM responses to 
U1Ap peptides than healthy individuals (Figure 1). Interesting, IgM anti-U1Ap-P16 IgM 
reactivity was significantly lower in both SLE and MCTD patients compared to healthy 
controls (p ≤ 0.04) (Figure 1). SLE patients showed trends toward higher IgM reactivity 
for U1Ap subunits than MCTD patients (P4, P6, P7, P10, P11 and P13 were the most 
antigenic U1Ap fragments against IgM with 1.3 fold higher levels in SLE than MCTD 
patients), but the differences were not significant (p > 0.05, Figure 1). Specifically, P7 
and P17 represented the biggest (137%) and smallest (96%) differences between the SLE 
and MCTD subsets. 
 
Auto-antigenic IgM response is directed to non-RNA recognition domain regions of 
U1Ap 
 To compare the IgM reactivity in the RNA recognition domain versus non-RNA 
recognition domain fragments of U1Ap, the average peptide reactivity corresponding to 
regions identified as RNA recognition motif (RRM) 1 (P1-P4), RRM2 (P14-17) and the 
non-domain area (P4-P13) were calculated in SLE, MCTD and healthy populations. 
Patients showed elevated IgM anti-U1Ap responses to non-domain areas of the U1Ap 
(P5-P13) when compared to RRM1 (P1-P4) and RRM2 (P14-P17) (Figure 1). However, 
only the SLE and not the MCTD patient subgroup exhibited significantly elevated 
average IgM response to peptides in U1Ap non-domain regions when compared to the 
average IgM reactivity for peptides covering RRM1 or RRM2 (p ≤ 0.003). The IgM 
response to the U1Ap C-terminal end, which encompasses RMM2, was noticeably lower 
in both SLE and MCTD patients than in control samples (Figure 1).   
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IgM derived U1Ap 3D epitope maps for SLE and MCTD patients 
The IgM reactivity for each U1Ap peptide monitored in sera from SLE and 
MCTD patients was used to create two independent epitope maps of U1Ap (Figure 2 and 
detailed protocol in Appendix 1). In general, the IgM reactivity was not always directed 
to exposed fragments of the U1Ap, given that superficial peptides appeared to have an 
equal chance to be highly antigenic (P7 in SLE and P9 in MCTD) or not (P17 in SLE and 
P4 in MCTD) (Figure 2). Likewise, different molecular structures like α-helices (P4), β-
sheets (P15) and loops (P8) seemed to elicit antigenic IgM responses to U1Ap. However, 
β-sheets were the least antigenic of all three forms (P15 and P16 in Figure 2). When 
comparing the SLE and MCTD subgroups, higher U1Ap IgM reactivity was directed to 
superficial peptides with α-helical structure in both SLE (P7) and MCTD (P4) (Figure 2). 
The lowest IgM responses were observed for peptides corresponding to exposed β-sheet 
fragments of the U1Ap in both SLE and MCTD (e.g., P16 in both SLE and MCTD 
patients in Figure 2).           
 
IgM anti-U1Ap titers discriminate between patients with and without kidney involvement 
 The IgM responses to specific U1Ap peptides (P1, P2, P4, P5, P12, P15 and P16) 
across the entire patient group significantly correlated with kidney involvement (p ≤ 
0.05). BLR analyses using all 17 U1Ap peptides confirmed that the combined IgM 
reactivity for P2, P8, P11, P14, P15 and P17 (referred to as “U1Ap kidney model”) 
represented the best predictor to identify patients with kidney disease (p ≤ 0.0001) 
(Figure 3A). Specifically, ROC analysis confirmed that the U1Ap kidney model had 
significant power (AUC = 0.828) to separate between patients with kidney and without 
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kidney disease with 85% specificity, 45% sensitivity and 73% overall accuracy to 
correctly categorize patients (p ≤ 0.005) (Figure 3B).  Furthermore, the analyses revealed 
that the capacity of the U1Ap kidney model to distinguish an SLE patient with or without 
kidney disease was not significantly different than that observed in patients with MCTD 
(p > 0.05).  
 
IgM anti-U1Ap reactivity patterns and lung involvement  
 No anti-U1Ap peptide responses in univariate analyses were found to 
significantly correlate with lung damage. However, BLR analysis revealed that the 
combined IgM response to peptides P4, P9, P12 and P15 (the “U1Ap lung model”) 
distinguished between patients with or without lung involvement similarly to the 
performance of the kidney model above (AUC = 0.822) (Figure 4A). The overall 
accuracy of the U1Ap lung model to classify patients was 79% with 81% sensitivity 77% 
specificity (Figure 4B). As expected, the capacity of the U1Ap lung model to identify a 
patient with or without lung disease was not significantly different when SLE or MCTD 
subsets were contrasted.          
 
Discussion  
 New markers that differ between SLE and MCTD patients are being described as 
the understanding of these autoimmune syndromes increases (Sasaki et al., 2011; Lage et 
al., 2012; Mesa et al., 2013; Jin et al., 2013). In the present study, the IgM reactivity for 
peptides covering the full length of the U1Ap was explored to find potential novel U1Ap 
antigens unique to either autoimmune disorder as well as to determine associations that 
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might exist between IgM responses to U1Ap and organ targeting. The present 
investigation reported differences between SLE and MCTD patients regarding their anti-
U1Ap responses, provided the first IgM derived epitope mapping of U1Ap for these 
autoimmune disorders, and describe two patterns of IgM anti-U1Ap peptide reactivity 
that are associated with kidney or lung disease.                 
 The mapping of the IgM response onto the predicted 3D structure of the full 
length U1Ap represented a unique approach to examine the behavior of the autoimmune 
reaction for this protein in SLE and MCTD patients (Figure 2), especially since only the 
U1Ap’s RRM1 NMR has been described (Varani et al., 2000). In concordance with a 
previous report (McClain et al., 2004), U1Ap fragments that do not participate in protein 
or RNA binding show the highest IgM antigenicity in both SLE and MCTD (P5-P13 in 
Figures 1 and 2). Nevertheless, only SLE but not MCTD patients showed significant 
differences when domains RRM1 and RRM2 were compared to non-domain areas (U1Ap 
amino acids 87-206, p ≤ 0.05). The present study revealed that bound and unbound 
region of U1Ap are capable of elicit an autoimmune response and therefore suggest that 
unbound regions of U1Ap are not sufficient to elicit IgM antigenicity. Consequently, 
other factor(s) like molecular mimicry from defective immune response to viral 
infections described by Migliorini et al. (2005) could be essential in promoting anti-
U1Ap IgM responses in SLE but not MCTD patients. Contrary to the common believe 
that antigenic fragments are located on superficial protein regions (McClain et al., 2004), 
the data suggest that the IgM response to U1Ap does not appear to rely only on peptide 
accessibility in the intact form of the protein. Consequently, it is reasonable to 
hypothesize that the IgM response in SLE and MCTD patients could form prior to U1Ap 
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reaching its native state or after deficient clearance of U1Ap apoptotic material like that 
reported by the deleterious role of granzyme B in autoimmune diseases (Casciola-Rosen 
et al., 1999; Mevorach, 2003). The fact that SLE and MCTD patients’ sera were unable 
produce an autoimmune reaction for U1Ap RRM2 (P14-P17 in Figures 1 and 2) when 
compared to U1Ap RRM1 (P1-P4) was not surprising given that RRM2 sequence differs 
by 78% from that of RRM1 and its binding capacity has been shown to not resemble that 
of a typical RNA binding protein (Lu and Hall, 1995). Taken all together, the 3D epitope 
map not only allows for visualization of the IgM antigenicity of U1Ap fragments 
determined by their location and molecular structure but also provides a basis to develop 
a new hypothesis regarding the IgM response to U1Ap (Figure 2).      
  The binomial analysis revealed that the combined IgM reactivity of six U1Ap 
peptides (P2, P8, P12, P14, P15 and P17) allowed the detection of kidney damage in 
either SLE or MCTD patients with an overall accuracy of 72% (p ≤ 0.005) (Figure 3). 
Interestingly, the power of the U1Ap kidney model did not significantly differ between 
SLE and MCTD with kidney malfunction (p ≤ 0.05). The present study describes for the 
first time an U1Ap model as a predictive serological biomarker for kidney disease. 
However, levels of neutrophil gelatinase-associated lipocalin (NGAL), soluble vascular 
cell adhesion molecule 1 (VCAM-1), Interleukin 6 (IL-6) and nucleosome have been 
described as molecular determinants for kidney disease only for SLE but not reported for 
MCTD patients (Yang et al., 2012; Pizarro et al., 2007; Brugos et al., 2012; Simón et al., 
2004). Currently, NGAL is considered the gold standard for the diagnosis and prognosis 
of kidney injury with sensitivity (70.8%) and specificity (87.5%) in SLE patients (Haase 
et al., 2009; Yang et al., 2012).  Nevertheless, previous research derived from NGAL has 
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not recognized the inclusion of MCTD patients therefore its power to detect kidney 
disease in these unrecognized illness is unknown. Consequently, the proposed U1Ap 
kidney model represents the only available blood marker for kidney disease for patients 
diagnosed with either SLE or MCTD.    
The combination of IgM reactivity for four U1Ap subunits (P4, P9, P12, and P15) 
had significant power to identify patients with lung disease diagnosed with either SLE or 
MCTD with an overall accuracy of 79% (p ≤ 0.002) (Figure 4). The U1Ap lung model 
did not show significant difference in predicting lung damage when SLE and MCTD 
were compared. However, lung biomarker homogeneity like the one observed in the 
present study has been reported in patients suffering from autoimmune disorders 
(Nishimaki et al., 1999). The proposed lung model is congruent with previous studies 
given that auto-antigenicity against U1Ap has been associated with lung disease in SLE 
and MCTD patients (Nishimaki et al., 1999; Bertoli et al., 2007; Cojocaru et al., 2011; 
Lian et al., 2012) and has even been shown to be elevated in three different types of lung 
cancer (Zhang et al., 2005 and 2008). Aside from these associations, no study has 
recorded the predicted accuracy of these correlations and, as a result, chest radiography 
has been the suggested method to diagnose lung injury (Levitt et al., 2013). Since 
evidence of lung damage is reported in both of these autoimmune syndromes and 
indicated to be the leading cause of mortalities in MCTD patients (Prakash, 1992; 
Pehlivan and Inanc, 2010; Allen et al., 2012), the U1Ap lung model should be considered 
as a new serological predictive factor for lung disease with the sensitivity and specificity 
of 81% and 77%, respectively, in patients with either SLE or MCTD (Figure 5). 
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 In summary, the results are in agreement with previous studies given that there is 
a prevalence of IgM anti-U1Ap reactivity in SLE but not MCTD patients (Figures 1). The 
IgM derived U1Ap epitope map showed that peptide accessibility is not sufficient to 
justify the contrasting autoimmune reactions observed in SLE and MCTD patients 
(Figure 2) and the data suggests that molecular mimicry from previous infection and/or 
deficient clearance of U1Ap apoptotic fragments are candidate factors for this difference. 
Consequently, these findings constitute additional molecular evidence to support the 
different etiology of these autoimmune disorders. Furthermore, for the first time, this 
work described two serological biomarkers with the predicted capacity of 72% of 
detecting kidney damage and 71% of identifying lung injury in patients diagnosed with 
either SLE or MCTD (Figures 4 and 5). With acknowledgement that additional validation 
of the U1Ap proposed models for identification of kidney and lung malfunction is 
required, future research on biomarkers associated with organ malfunction in SLE 
population should strongly consider the recognition of MCTD patients given the great 
number of overlapping characteristics shared by these two autoimmune syndromes.   
 
 
 
 
34 
 
 
Table 1: U1A protein peptides characterization 
 
 
Peptide 
Number 
Peptide 
 Position Peptide Sequence 
Peptide 
 length Reference 
P1 1–11 MAVPETRPNHT 11 Barakat et al. (1991) 
P2 35–58 SQFGQILDILVSRSLKMRGQAFVI 24 Barakat et al. (1991) 
P3 47–59 RSLKMRGQAFVIF 13 Arbuckle et al. (1998) 
P4 60-95 KEVSSATNALRSMQGFPFYDKPMRIQYAKTDSDIIA 36 No previously tested 
P5 96–103 KMKGTFVE 8 Poole et al. (2009) 
P6 112-119 KPKSQETP 8 Somarelli et al. (2011)
P7 118–127 TPATKKAVQG 10 Poole et al. (2009) 
P8 143–154 GMPPMTQAPRIM 12 Poole et al. (2009) 
P9 159–178 GQPPYMPPPGMIPPPGLAPG 20 Poole et al. (2009) 
P10 165–172 PPPGMIPP 8 Talken et al. (2001) 
P11 178-185 GQIPPGAM 8 Somarelli et al. (2011)
P12 180–193 IPPGAMPPQQLMPG 14 Poole et al. (2009) 
P13 196-203 PPAQPLSE 8 Somarelli et al. (2011)
P14 204-235 NPPNHILFLTNLPEETNELMLSMLFNQFPGFK 32 No previously tested 
P15 236–242 EVRLVPGR 8 Poole et al. (2009) 
P16 239–251 LVPGRHDIAFVEF 13 Arbuckle et al. (1998) 
P17 257–282 AGAARDALQGFKITQNNAMKISFAKK 26 Barakat et al. (1991) 
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Figures Legends 
Figure 1: SLE but not MCTD patients show predominant IgM response to U1Ap 
subunits. The diagram under U1A protein is a graphical representation of the linear 
structure of this protein where RNA recognition motif 1 (RRM1) and 2 (RRM2) are 
labeled. The amino acids covered by each of the peptides (P1-P17) are indicated under 
peptide position. The red, blue and gray columns correspond to SLE (n = 56), MCTD (n 
= 26) and healthy (n = 10) individuals, respectively. The lines on top of each column 
represent the standard error.   
 
Figure 2: U1A protein epitope map for IgM antigencity in SLE and MCTD patients. 
The IgM optical density percentage (OD%) based on the healthy group IgM reactivity 
obtained from  SLE (top) and MCTD (bottom) patients was mapped onto the 3D structure 
of U1A protein. The IgM antigenic scale is included at the bottom of the figure where 
blue and red represent the lowest and highest IgM reactivity for U1A protein, 
respectively. Gray areas on the SLE and MCTD epitope maps correspond to regions of 
unknown IgM antigenicity since no peptide covers these specific fragments. The 
rectangle embedded in the middle represents the U1A protein 3D structure where RNA 
recognition motif 1 (RRM1) is labeled in red, RRM2 is colored in blue while the gray 
fragments are regions free of RNA and protein interactions.  
 
Figure 3: IgM reactivity for U1Ap is a candidate marker for kidney damage. The 
observed IgM response to U1A protein (U1Ap) peptides was analyzed by binomial 
logistic regression (BLR) to assess which peptide combination increase could 
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significantly identify patients with kidney damage in either SLE or MCTD populations (p 
≤ 0.05). The classification ability of each of these peptides and predicted models were 
corroborated by receiving operating characteristic (ROC) curves analysis (p ≤ 0.05) A. 
ROC curves revealed the power of U1A peptides in classifying patients with kidney 
damage. In the graph, the peptides and predicted U1Ap kidney model are on the xaxis 
while the area under the curve (AUC) resulting from ROC curves analysis is indicated on 
the y axis.  The larger the number, the higher the probability of identifying an individual 
with kidney disease compared to a healthy individual. The lines on top of each column 
correspond to standard deviation.  The p values ≤ 0.05, ≤ 0.001 and 0.0001 are 
represented with one (*), two (**) or three (***) asterisks, respectively. B. Distribution 
of patients with kidney damage based on the U1Ap kidney model. Patients with 
evidence of kidney damage and healthy individuals are on the x axis while the predicted 
probabilities obtained from BLR analysis are on the y axis. The black and white dots 
indicate true positive (TP) and true negatives (TN) while the crosses represent either false 
positives (FP) or false negatives (FN). A cut off value of 0.5 (from a range of 0 to 1) was 
selected to allow equal chances to FP and FN (p ≤ 0.05).    
 
Figure 4: IgM anti-U1Ap titers are potential biomarkers for lung damage. The IgM 
reaction for U1A protein (U1Ap) peptides was analyzed by binomial logistic regression 
(BLR) to uncover peptide combinations with power to discern between patients with lung 
damage and healthy individuals in either SLE or MCTD populations (p ≤ 0.05). The 
grouping capability of each of these peptides and predicted models were corroborated by 
receiving operating characteristic (ROC) curves analysis (p ≤ 0.05) A. ROC curves 
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showed the classification power of the U1Ap lung model. In the graph, the peptides and 
predicted U1Ap lung model and area under the curve (AUC) resulting from ROC curves 
analysis are on the x and y axes.  The bigger the AUC, the higher the classification power 
for lung disease. The lines on top of each column correspond to standard deviation. The 
asterisks (***) represent p ≤ 0.0001. B. Segregation of patients with lung damage 
utilizing the U1Ap lung model as classifier. In the plot, patients and predicted 
probabilities of kidney damage are on the x and y axes. The black and white dots indicate 
true positive (TP) and true negatives (TN), respectively, while the crosses represent either 
false positives (FP) or false negatives (FN). A cut off value of 0.5 (from a range of 0 to 1) 
was selected to allow equal chances to FP and FN (p ≤ 0.05). 
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Figure 1:  SLE but not MCTD patients show predominant IgM response to U1Ap 
subunits 
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Figure 2: U1A protein epitope map for IgM antigencity in SLE and MCTD patients. 
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Figure 3: IgM reactivity for U1Ap is a candidate marker for kidney damage. 
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Figure 4: IgM anti-U1Ap titers are potential biomarkers for lung damage. 
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III. CHAPTER 2 
 
Production of spliceosomal derived biomarkers for identification of SLE and MCTD  
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Introduction 
 Systemic Lupus Erythematosus (SLE) and Mixed Connective Tissue Disease 
(MCTD) are systemic autoimmune disorders with overlapping clinical manifestations 
that possess aberrant immune responses against common auto-antigens (Zdrojewicz et al., 
1999; Egner 2000; Greidinger and Hoffman , 2001; Riemekasten and Hahn, 2005; Neogi  
et al., 2006; Liu and Ahearn, 2009). Despite its description as an independent auto-
immune disease (Sharp et al., 1972), the classification of MCTD as distinct from SLE 
remains controversial because of the high number of common clinical features between 
SLE and MCTD patients (López-Longo et al., 1994; Aringer et al., 2005; Swanton et al., 
2005; Venables, 2006; von Bierbrauer et al., 2008; Nowicka-Sauer et al., 2012). 
Nevertheless, the concept of MCTD has been reported as a useful definition in clinical 
practice (Zdrojewicz et al., 1999; Venables, 2006; von Bierbrauer et al., 2008; Nowicka-
Sauer et al., 2012), and clinical and serological features segregate the two illnesses 
(Isenberg et al., 2007; Breda et al., 2010). The American College of Rheumatology 
(ACR) has created universal classification parameters for SLE (Hochberg, 1997); 
however, four different criteria sets exist for MCTD patients, with the Alarcόn-Segovia 
criteria being the most widely accepted (Amigues et al., 1997).  
 Currently, there is no single test with sufficient specificity and sensitivity to 
discriminate between SLE and MCTD, which has hampered the identification of MCTD 
as a separate syndrome (Egner 2000; Reveille, 2004; Perkins et al., 2008; Liu and 
Ahearn, 2009; Hoffman et al., 2012). A positive diagnosis by any set of criteria requires a 
patient to exhibit at least four clinical symptoms and/or tests out of those included in each 
list, which can take years to develop (Liu and Ahearn, 2009; Hoffman et al., 2012). 
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Moreover, traditional laboratory tests are performed with numerous commercially 
available kits that can vary in principle and cut-off values, which may alter the final 
results and diagnoses (Egner 2000; Reveille, 2004; Mahler et al., 2005; Isenberg et al., 
2007; Chiaro et al., 2011). These and other factors complicate proper diagnosis of these 
two closely related and overlapping illnesses.  
 Previous investigations have demonstrated that SLE and MCTD patients often 
exhibit 1000-fold greater auto-reactivity to subunits of the U1 small nuclear 
ribonucleoprotein particle (snRNP) than to any other cellular component (Hoet et al., 1993; 
Vlachoyiannopoulos et al., 1996). The U1 snRNP is an RNA-protein complex that is 
responsible for pre-mRNA processing and is composed of 10 proteins (U1-70K, U1A, U1C 
and seven Smith antigen (Sm) proteins) (Luyckx et al., 2005; Mesa et al., 2008; Buratti et al., 
2010; Somarelli et al., 2010). In general, previous studies aimed at finding biomarkers for 
SLE and MCTD have focused on IgG-specific responses to nuclear components, including 
the U1 snRNP; however, some studies have revealed differential IgM reactivity for nuclear 
components in SLE and MCTD patients (Zhang et al., 1995; Vlachoyiannopoulos et al., 
1996; Witte et al., 1998; Palafox Sánchez et al., 2009). Yet, the potential use of the IgM 
response as a molecular tool to classify SLE and MCTD patients has not been fully 
explored.      
 To determine whether SLE and MCTD represented distinct disorders and test 
whether the two patient groups can be segregated, the IgG- and IgM-specific responses of 
patients with SLE and MCTD and healthy individuals against 15 different U1 snRNP 
peptides (named P1-15) were evaluated by indirect enzyme-linked immunosorbent assays 
(ELISAs). Interestingly, higher IgG-specific reactivity for U1 snRNP peptides was 
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observed  in individuals with SLE or MCTD compared to healthy individuals, but 
elevated IgM responses in SLE patients compared to those with MCTD and healthy 
adults. The IgM response to two peptides, P4 and P10 (P4/P10), exhibited 71.3% 
accuracy in segregating between these two autoimmune disorders (p ≤ 0.05). In 
summary, these data support the notion that SLE and MCTD are, indeed, distinct 
disorders and highlight the potential clinical use of the IgM anti-U1 snRNP system as a 
molecular tool to assist in the classification of SLE and MCTD patients.  
 
Materials and Methods 
Collection and preparation of sample sera 
Sera were obtained from whole blood of 122 patients previously diagnosed with 
SLE (n=81) or MCTD (n=41) and 31 healthy individuals. Samples were collected 
following the Institutional Review Board (IRB) accepted protocols of the University of 
Miami (IRB numbers: 200307-24 and 200402-86) and Florida International University 
(IRB number: 040308-00). The SLE and MCTD patients (collectively refer as ill or 
patient group) were clinically diagnosed according to the American College of 
Rheumatology (ACR) criteria and the Alarcόn-Segovia criteria, respectively, along with 
clinician judgment (Amigues et al., 1996; Hochberg, 1997). The laboratory tests 
considered in the present study were commercially performed by Quest Diagnostic 
Incorporated and their positive values are included in Table 3. Details of the flare or 
remission period in these SLE and MCTD patients were not recorded at the moment of 
whole blood collection and therefore disease activity for these SLE and MCTD patients is 
not been considered in this study.     
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Selection of U1 snRNP peptides 
 The U1 snRNP peptides included were previously reported in Somarelli et al., 
(2011) and commercially synthesized by BioMatik Corporation (Wilmington, DE, USA) 
The observed IgM reactivity for each of the U1 snRNP peptides was ranked from most 
(1) to least (15) antigenic for each disease state (Table 3).     
 
Monitoring IgM reactivity for U1 snRNP peptides by indirect ELISAs 
 The indirect ELISA protocol employed to assess IgM reactivity for each peptide 
and sample included was previously described (Somarelli et al., 2011). The average IgM 
derived OD value for each peptide was normalized using the average OD value of the 
healthy group per peptide examined and was expressed as OD% based on the following 
formula (Muñoz-Paredes et al., 1999):  
ܱܦ% =	ቀ ௑ത	ை஽	௢௙	௦௔௠௣௟௘	௜௡	௉௫௑ത	ை஽	௢௙	௖௢௡௧௥௢௟	௚௥௢௨௣	௜௡	௉௫ቁ × 100 
 
where “ തܺ	OD of sample in Px” is the average OD value of the sample group (SLE or 
MCTD) and “ തܺ	OD of control in Px” indicates the average OD of the control group 
(healthy group) from each of the peptides included in this study (P1-P15). To evaluate the 
relative reactivity contributed by IgM and IgG in SLE, MCTD and healthy populations, 
the average OD values from IgG-specific ELISAs previously reported by Somarelli et al., 
(2011), which used the same samples and U1 snRNP peptides included in this study, 
were re-analyzed and converted to OD% using the equation described above (Muñoz-
Paredes et al., 1999).   
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Statistical analyses 
Significant differences in IgG and IgM reactivity between patients (SLE and 
MTCD) and healthy groups and between SLE and MCTD individuals for each of the 
peptides was assessed using independent sample t-tests. Clinical tests and symptoms were 
evaluated by independent sample t-tests (numerical data) or Chi (X) squared tests 
(nominal data). Receiver Operating Characteristic (ROC) curves were generated with the 
PASW software package (version 18). Forward binary logistic regression (BLR) analyses 
using the IgM and IgG anti-U1 snRNP titers in ill (SLE and MCTD) and healthy individuals 
as well as SLE and MCTD patients were performed with the PASW software package 
(version 18). P-values ≤ 0.05 were considered statistically significant for all tests. 
Correlations between each IgM anti-U1snRNP peptide titers and IgM anti-Rheumatoid 
Factor (RF) antibody titers were performed using PASW software package (version 18), 
however; since none of them were significantly correlated, they were not further considered 
in this study.    
 
Results 
IgM anti-U1 snRNP reactivity is elevated in SLE but not MCTD patients 
The IgM response to U1 snRNP peptides was monitored via indirect ELISAs and 
reported as OD% (Figure 5A). IgM anti-U1 snRNP titers were significantly higher in the 
SLE group than either the MCTD population or healthy individuals (p ≤ 0.05). In fact, in 
many instances, IgM responses to U1 snRNP peptides in MCTD patients were equal to or 
below those exhibited by healthy individuals (P3, P4 and P9-P15 in Figure 5A). The 
discrimination capacity of IgM-anti-U1 snRNP peptide ELISAs was assessed by ROC 
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curve analysis and indicates that IgM reactivity for P1 and P13 provides significant 
power to classify SLE and MCTD patients; however, none of the IgM responses were 
sufficient to discern SLE and MCTD from non-disease controls with statistical 
significance (Figures 1C-D and Appendix 2).  
 
SLE and MCTD patients exhibit an elevated IgG response for U1 snRNP peptides  
As previous studies have reported (Fries et al., 1984; Nishimaki et al., 1999; 
Lindorfer et al., 2001; Routsias et al., 2010; Ryu et al., 2011; Somarelli et al., 2011; ), the 
IgG-mediated reactivity for each of the U1 snRNP peptides was significantly higher in 
both SLE and MCTD populations than in the healthy group; however, IgG reactivity does 
not differ between the two autoimmune disorders (Figure 5B). ROC curve analyses on 
IgG anti-U1 snRNP titers per peptide ascertain their individual ability to discern between 
patients (SLE and MCTD) and healthy individuals and between SLE and MCTD patients 
(Figure 5C-D, respectively; and Appendix 2). As previously reported (Somarelli et al., 
2011), all but IgG anti-P2 responses were capable of significantly discriminating ill (SLE 
and MCTD) and healthy individuals with IgG anti-P4 being the best (p ≤ 0.05); however, 
none of the IgG anti-U1 snRNP titers had a statistically significant ability to classify SLE 
and MTCD patients (Figure 5D).  
 
Differential auto-immune responses and symptoms are observed in SLE and MCTD 
patients 
 The results showed that SLE and MCTD patients exhibit significantly different 
IgM anti-U1 snRNP reactivity (p ≤ 0.05) despite similar IgG-mediated antigenicity for 
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the same peptides (Figures 1A-B). To further support the idea that SLE and MCTD 
represent distinct auto-immune illnesses, statistical analysis of 42 standard laboratory 
tests were performed with blood samples from the SLE and MCTD patient cohort. These 
analyses revealed that 11 out of the 42 clinical tests were significantly different in SLE 
and MCTD patients (p ≤ 0.05) (Table 2). Specifically, differences were observed in tests 
designed to detect nuclear auto-antigens (RNP, Sm, Scl70, dsDNA, elevated DNA), renal 
function (creatine phosphokinase levels, renal proteinuria, renal hematuria) and immune 
system components (C3 and C4 complement levels) (p ≤ 0.05). These findings support 
the idea that SLE and MCTD represent distinct autoimmune manifestations, with specific 
antigenic targets and antibody class reactivities.         
 Similarly, statistical assessment of 40 clinical symptoms from patients in the SLE 
and MCTD cohort indicated that 16 out of the 40 clinical characteristics evaluated were 
significantly different between SLE and MCTD patients (Table 4). Most of the 
significantly different clinical manifestations involved the skin and joints of these 
patients; however, the data also confirmed that neuropsychiatric disorders and problems 
in the circulatory system were also significantly different between the two groups.  Once 
again, the fact that clinical symptoms differ in SLE and MCTD populations supports the 
hypothesis that these maladies may be clinically distinct. 
 
Antibody class reactivities for U1 snRNP peptides segregate among SLE, MCTD and 
healthy individuals 
 The IgM and IgG responses for all U1 snRNP peptides were combined in a BLR 
to determine which peptide and auto-antibody combinations might provide the highest 
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segregation between patient (SLE and MCTD) and healthy populations. These analyses 
revealed that the combined IgG-specific response for P2, P4, P5, P10 and P13 has the 
greatest capacity to discern between sick and healthy individuals with an overall accuracy of 
94% (p ≤ 0.05) (Figure 6A) where the probability of correctly predicting a patient with 
either SLE or MCTD is higher than that for correctly predicting a healthy individual 
(96.7% and 83.9%, respectively).  
 Additional BLRs were performed with the individual IgG and IgM reactivities for 
each U1 snRNP peptide to assess which peptide and Ig class combination significantly 
discriminates between SLE and MCTD patients. These analyses indicated that only the 
combined IgM response for P4 (U1C) and P10 (U1A) significantly discriminate between 
SLE and MCTD patients, with an overall accuracy of 71.3% (p ≤ 0.05) (Figure 6B). 
Remarkably, most of the classification power derives from the proper classification of 
SLE patients (95.1%) rather than proper grouping of MCTD patients (24.4%) (Figure 
6B). Consequently, the data demonstrate that by first combining the IgG reactivity for P2, 
P4, P5 and P10 and then the titers for IgM anti-P4/P10, an overall accuracy of 73.9% at 
discriminating among SLE, MCTD and healthy groups can be achieved.  
  
Comparing the power of IgM anti-P4/P10 with conventional clinical tests  
   To determine the classification power of the proposed IgM-specific P4/P10 
ELISA-based system, ROC curves were used to compare this system with eight 
conventional clinical tests. The individual IgM reactivities for P1 and P13 were also 
included in the ROC curves analyses because they discriminate between SLE and MCTD 
(Figure 5D). The 11 laboratory tests that significantly differ between SLE and MCTD 
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patients were performed only in a small portion of each sub-population (Table 2).  Not all 
tests could be analyzed as result of the reduced sample size. Instead, eight of the most 
frequently-used laboratory tests that are part of the classification criteria to diagnose SLE 
or MCTD were included in the ROC curve analysis (FANA titers, dsDNA ELISA, 
elevated serum DNA titers and positive results for RNP, Sm, SSA, SSB and Scl-70) 
(Egner, 2000; Mahler et al., 2005; Isenberg et al., 2007; Breda et al., 2010). When using 
the subset of individuals for whom clinical test results were available (SLE = 59 and 
MCTD = 24), the IgM anti-P4/P10 titers and IgM anti-P1 reactivity displayed the greatest 
discrimination capacity to classify SLE and MCTD patients (p ≤ 0.05) (Figure 7 and 
Appendix 2). The ROC curves confirmed that among the conventional tests evaluated, 
elevated DNA and positive results for Sm are the third and fourth best at significantly 
segregating SLE and MCTD (p ≤ 0.05).  
 
Improving the discriminatory capacity of IgM anti-P4/P10 titers 
 The BLR analyses were performed to assess whether the combination of the IgM 
anti-P4/P10 system and any of the eight laboratory tests employed to diagnose SLE or 
MCTD (FANA titers, dsDNA ELISA, elevated serum DNA titers and positive results for 
RNP, Sm, SSA, SSB and SCL-70)4; 15-16; 21-22 might provide greater capacity to 
distinguish between these syndromes. The individual IgM reactivities for P1 and P13 
were considered in this BLR analysis because they showed a significant ability to classify 
SLE and MCTD patients (p ≤ 0.05) (Figure 5D).  The BLR analyses indicated that the 
combination of the IgM-based reactivity for P4/P10 and an elevated DNA assay represent 
the best combination of variables to segregate SLE from MCTD when compared with 
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IgM anti-P4/P10, -P1, or-P13 and any single laboratory test examined (p ≤ 0.0001) 
(Figure 7 and Appendix 2). None of the other clinical test combinations improved the 
power of discrimination between SLE and MCTD patients over that exhibited by the 
individual tests alone (p ≤ 0.05). The analyses also suggest that, when combined with the 
standard elevated DNA test, the IgM response against P4/P10 may be useful in enhancing 
the current segregation of SLE from MCTD.  
 
Discussion 
 Despite the fact that MCTD was described as a distinct rheumatic syndrome in 
1972 (Sharp et al., 1972), placement of this disorder as a separate auto-immune illness 
remains controversial. Opinions are divided regarding classification of MCTD as a 
separate malady due to the number of auto-antigens and clinical symptoms that show 
overlap with SLE (López-Longo et al., 1994; Aringer et al., 2005; Swanton et al., 2005; 
Venables, 2006; von Bierbrauer et al., 2008; Nowicka-Sauer et al., 2012). The immune 
responses of SLE and MCTD patients for overlapping ‘self’ antigens coupled with the 
diversity of commercially available clinical tests with differing protocols, reagents and 
cut-off values have impeded the development of standard and uniform assays to segregate 
these syndromes (Egner, 2000; Mahler et al., 2005; Neogi et al., 2006; Liu and Ahearn, 
2009). With the exception of a few studies (Vlachoyiannopoulos et al., 1996; Zhang et al., 
1995; Witte et al., 1998; Palafox Sánchez et al., 2009), most investigations have focused 
on IgG-mediated reactivity toward specific antigens as potential molecular tools to 
differentiate between SLE and MCTD patients (Fries et al., 1984; Lindorfer et al., 2001; 
Routsias et al., 2010; Ryu et al., 2011). Given that SLE and MCTD patients are 
53 
 
characterized by elevated blood titers of multiple Ig classes, including IgM (Pollar and 
Tan. 1985; Kingsmore et al., 1989; Vlachoyiannopoulos et al., 1996), it was hypothesized 
that IgM responses to a number of U1 snRNP peptides may allow us to increase the 
present discrimination between SLE and MCTD and provide additional molecular 
evidence to claim the independent nature of these two disorders.  
The data indicate that the combined IgM reactivity for fragments of U1C (P4) and 
U1A (P10) is capable of classifying SLE and MCTD patients with an accuracy of 71.3% 
(Figure 6B), a value higher than previously reported peptide-based immunoassays that 
have been used to segregate these disorders (Mahler et al., 2005). These findings are in 
concordance with previous reports, which revealed a preponderance of IgM anti-U1 
snRNP antibodies in SLE, but not MCTD patients (Zhang et al., 1995; 
Vlachoyiannopoulos et al., 1996). Therefore, the present work is congruent with prior 
investigations and demonstrates the potential utility of differential Ig class responses as a 
classification tool for SLE and MCTD.  The current work also provides molecular 
evidence to support the distinct etiology of these syndromes. 
 The binomial analyses identified combinations of laboratory tests and/or peptide 
reactivities that significantly discern between these maladies. Interestingly, the IgM anti-
P4/P10 ELISA-based system provided the greatest capacity to segregate between SLE 
and MCTD disorders and eight other conventional laboratory tests (p ≤ 0.0001) (Figure 
7). Additionally, we revealed that the combination of IgM anti-P4/P10 antigenicity with 
the elevated DNA test segregated 79.8% of SLE and MCTD patients, even in the smaller 
subset of patients for whom clinical test results were available (n = 59 for SLE and n = 24 
for MCTD) (Figure 7). It is not surprising that the dsDNA test contributes to the 
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differentiation of these diseases given that antibodies against DNA have been detected in 
approximately 70% of SLE patients and shows 95% specificity for this disorder 
(Reveille, 2004; Breda et al., 2010). Yet, the fact that the dsDNA test alone exhibits a 
lower ability to segregate SLE and MCTD patients (66.4%) than the IgM anti-P4/P10 
system (73.1%), indicates the significant contribution of this ELISA-based system in 
discerning between these two maladies (Figure 7).   
 A total of 16 out of 40 clinical manifestations studied significantly differ between 
SLE and MCTD patients (Table 4). On average, MCTD patients exhibited hand/joint 
swelling and muscle weakness with 25% higher frequency than SLE patients. Similarly, 
malar and discoid rashes were found to be more prevalent in the SLE than the MCTD 
group (46% and 10% versus 13% and 0%, respectively). These findings are in 
concordance with previous studies that reported these clinical manifestations as key 
features in SLE or MCTD patients (Perkins et al., 2008; Hoffman et al., 2010). Evidence 
of mental illness was also found to be 32% higher in MCTD than SLE patients. Although 
selection bias of the clinicians diagnosing these disorders cannot be ruled out, the results 
obtained from a subset of SLE and MCTD patients suggest that the immune response of 
SLE patients seems to be directed to skin areas on the face while those suffering from 
MCTD appear to develop a more systemic immune response that attacks the skin, joints 
and muscles throughout various parts of the body. Furthermore, these findings highlight 
specific clinical manifestations that appear to differ between SLE and MCTD patients 
and should be considered as clinical evidence that they may be distinct diseases.  
  Overall, this study further highlights the current challenges in developing quantitative 
tests for the classification of SLE and MCTD and therefore the recognition of MCTD as 
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a separate entity (Egner, 2000; Mahler et al., 2005; Neogi et al., 2006; Liu and Ahearn, 
2009). Here, a novel approach based on differential antibody class (IgM and IgG) 
responses has been described as a mechanism to discriminate between SLE and MCTD 
patients with better accuracy than conventional laboratory tests currently employed as 
part of the classification criteria to diagnose these syndromes. In addition, the data 
revealed contrasting frequencies of clinical symptoms characterizing these auto-immune 
syndromes whereby SLE patients showed a concentrated auto-immune manifestation 
directed to skin areas on the face while those suffering from MCTD developed more 
systemic immune responses that attack the skin, joints and muscles throughout various 
parts of the body.   Consequently, these results provide further evidence to support the 
fact that there are molecular and clinical aspects of SLE and MCTD to indicate that 
these diseases are, indeed, two distinct autoimmune syndromes.   
 
 
 
 
 
 
 
 
 
 
56 
 
Table 2: Clinical tests evaluated in SLE and MCTD patients 
 
 Clinical test name SLE MCTD P value Positive Total Positive Total 
SL
E 
/ M
C
TD
  s
pe
ci
fic
 
Fluorescence antinuclear Abs titers 76.56% 64 90.63% 32 0.3860 
Fluorescence antinuclear Abs pattern 86.30% 73 85.71% 35 0.4430 
IgG anticardiolipin positive 23.53% 68 23.81 21 0.8480 
IgM anticardiolipin positive 6.06% 66 18.18% 22 0.0870 
Rheumatoid factor titer by latex 8.33% 12 20.00% 5 0.0870 
IgM anti-rheumatoid factor Abs by ELISA 41.86% 43 38.10% 21 0.8480 
IgM anti-rheumatoid factor Abs titer 20.93% 43 23.81% 21 0.9040 
RNP positive 84.00% 75 100% 40 0.0080 
Sm positive 60.27% 73 28.21% 39 0.0010 
SSA positive 58.11% 74 47.22% 36 0.2820 
SSB positive 21.62% 74 11.11% 36 0.1800 
SCL 70 positive 1.45% 69 16.13% 31 0.0040 
Elevated serum DNA titer 64.10% 78 29.73% 37 0.0010 
Anti-dsDNA positive 49.35% 77 27.03% 37 0.0010 
IgG anti U1-70K Abs* 37.84% 37 55.00% 20 0.2130 
IgG anti SmB/B' Abs* 44.12% 34 50.00% 20 0.7700 
IgG anti SmD Abs* 73.53% 34 63.16% 19 0.7260 
Anemia 25.00% 80 22.50% 40 0.7630 
Hemolytic anemia 3.23% 62 8.33% 12 0.4120 
White blood count 8.77% 57 6.06% 33 0.2780 
Leukopenia 11.54% 78 12.50% 40 0.8780 
Lymphopenia 36.71% 79 42.5% 40 0.5400 
Thrombocytopenia 10.13% 79 2.50% 40 0.1370 
Thrombocytosis 5.13% 78 2.56% 39 0.5180 
Creatine phosphokinase positive 91.07% 56 74.29% 35 0.4770 
Creatine phosphokinase elevated 7.02% 57 25.71% 35 0.0120 
Serum creatinine 10.53% 76 5.26% 38 0.4500 
Renal cellular cast 10.67% 75 2.56% 39 0.1280 
Renal proteinuria 40.85% 71 13.51% 37 0.0040 
Renal hematuria 18.92% 74 2.70% 37 0.0180 
C reactive protein 20.83% 72 18.18% 33 0.4850 
Elevated C reactive protein 23.61% 72 20.59% 34 0.7290 
Low C3 complement 41.77% 79 15.00% 40 0.0030 
C3 complement level 56.96% 79 82.50% 40 0.0001 
Low C4 complement 48.10% 79 30.77% 39 0.0730 
C4 complement level  44.30% 79 69.23% 39 0.0001 
Erythrocyte sedimentation rate 57.89% 79 52.27% 40 0.8530 
Elevated erythrocyte sedimentation rate 56.48% 76 55.00% 40 0.8710 
G
en
er
al
 IgG anti-rheumatoid factor Abs 41.86% 43 42.86% 21 0.9400 
IgG anti-rheumatoid factor Abs titer 41.86% 43 38.10% 21 0.8480 
Immunoglobulin isotypes for RF factor 79.07% 43 76.19% 21 0.5300 
Lymphocyte absolute value 74.14% 58 75.86% 29 0.3460 
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Table 3: Overview of U1 snRNP peptides used in the study  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peptide 
number 
U1 snRNP 
protein 
Peptideregion  
(amino acid range) 
Peptide 
sequence 
Observed IgM 
 reactivity ranked 
SLE MCTD 
1†* U1A 196-203 PPAQPLSE 1 6 
2†* Sm E 63-70 EIHSKTKS 3 2 
3†* Sm F 46-53 NTEEYIDG 12 9 
4†* U1C 90-97 GMMPAPHM 11 8 
5* U1-70K 337-344 PDGPDGPE 6 4 
6†* Sm B 83-90 EGPPPKDT 2 3 
7†* Sm G 1-8 MSKAHPPE 5 5 
8†* Sm D3 20-27 CETNTGEV 4 1 
9†* Sm F 77-84 EEEEDGEM 9 12 
10†* U1A 112-119 KPKSQETP 13 13 
11†* Sm D2 14-21 EELQKREE 10 11 
12†* Sm D1 22-29 GTQVHGTI 8 10 
13†* U1A 178-185 GQIPPGAM 14 14 
14†* U1-70K 325-332 APPDDGPP 15 15 
15†* U1C 66-73 PFSAPPPA 7 7 
The peptide designation, region and sequences as well as the U1 snRNP protein column displayed in this table 
(first four columns) were previously published by Somarelli et al. (2011). The observed IgM antigenicity 
(columns 5 and 6, from left to right) was ranked from 1 to 15 where “1” represents the peptide with the highest 
IgM antigenicity and “15” indicates the peptide with the lowest IgM antigenicity. Daggers (†) indicate IgM 
peptide antigenicities that significantly differ between SLE and MCTD patients while the asterisks (*) represent 
IgG reactivities for U1 snRNP peptides that significantly differ between ill (SLE and MCTD) and healthy 
individuals (p ≤ 0.05). 
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Table 4: List of clinical symptoms observed in SLE and MCTD 
 
Clinical symptom name SLE MCTD p-value Positive Total Positive Total 
Skin telangiectasia 5% 79 15% 40 0.0650 
Skin nasal/oral ulcers 29% 79 23% 39 0.4880 
Raynaud’s syndrome 53% 80 85% 40 0.0001 
History of hand swelling 41% 81 61% 41 0.0120 
Observed hand swelling 19% 81 39% 41 0.0140 
Acrosclerosis 4% 80 26% 38 0.0001 
Skin digital pitting 8% 80 8% 39 0.9700 
Proximal scleroderma 3% 79 0% 39 0.3160 
Skin alopecia 58% 80 72% 39 0.1310 
Malar rash 46% 78 13% 39 0.0001 
Discoid rash 10% 78 0% 39 0.0380 
Skin rash 33% 78 38% 39 0.5840 
Skin photosensitivity 57% 76 58% 38 0.8940 
Skin calcinosis 1% 79 5% 38 0.2000 
Sicca, xerophthalmia and  
xerostomia 49% 81 66% 41 0.1330 
Erosive inflammatory arthritis 43% 23 45% 20 0.9200 
Lymphadenopathy 24% 79 20% 40 0.6180 
Fever 22% 78 15% 40 0.7780 
Proximal muscle weakness 29% 76 49% 39 0.0360 
Myositis 6% 79 27% 33 0.0020 
Myalgia 54% 80 48% 40 0.8970 
Morning stiffness 53% 73 64% 36 0.3000 
Swelling of three or more 
joints 42% 78 63% 40 0.0380 
Joint tenderness 35% 79 69% 39 0.0010 
Joint swelling 29% 78 63% 40 0.0010 
Symmetric swelling 27% 78 64% 39 0.0001 
Rheumatoid nodule 6% 77 10% 40 0.5000 
Arthralgia 82% 79 84% 38 0.7950 
Neuropathy 31% 77 28% 40 0.6810 
Seizure 4% 80 0% 40 0.2150 
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Table 4, continuation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical symptom name 
SLE MCTD 
p-value 
Positive Total Positive Total 
Psychosis 3% 79 0% 39 0.3160 
Neuropsychiatric disorder 19% 78 51% 39 0.0001 
Hypomotility in cine 
deglutition esophageal 41% 78 58% 40 0.0890 
Pulmonary fibrosis 22% 45 23% 26 0.6330 
Pleuritic pain or rubbing heard 37% 78 23% 39 0.1250 
Pericarditis 30% 73 18% 39 0.1610 
Avascular necrosis 3% 74 0% 33 0.3040 
Clotting 1% 75 12% 34 0.0160 
Myocardial infarction 0% 73 11% 35 0.0030 
Stroke 6% 81 2% 41 0.3570 
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Figure legends 
Figure 5: Contrasting IgM-specific anti-U1 snRNP peptide responses observed in 
SLE and MCTD patients. (A) and (B) represent the average percent optical density 
(OD%) values for the IgM class and IgG classes, respectively. Peptide number and OD% 
are on the x and y axes, respectively. The black, gray and white bars symbolize the 
average OD% of SLE, MCTD and healthy groups, respectively. (†) and (*) indicate 
significantly different OD% between SLE and MCTD as well as patients and healthy 
populations, respectively (p ≤ 0.05). (C) and (D) correspond to the area under the curve 
(AUC), derived from ROC curves, for ill (SLE and MCTD) vs. healthy individuals as 
well as SLE vs. MCTD patients, respectively. Peptide number per Ig class and their AUC 
values are indicated on the x and y axes, respectively.  () and () symbolize 
significantly different AUC between patients and healthy individuals as well as SLE and 
MCTD patients, respectively (p ≤ 0.05). The dotted lines in C and D indicate the cut-off 
value (0.5). Black bars in all graphs represent standard error of the mean. 
 
Figure 6: Identification of a two-step ELISA system for classification of SLE, 
MCTD and healthy individuals. (A) The combination of IgG-mediated anti-
P2/P4/P5/P10/P13 provides the best segregation between SLE and MCTD vs non-disease 
controls. The distribution of ill (SLE and MCTD) and healthy individuals and the 
predicted combined IgG-mediated reactivity are represented on the x and y axes, 
respectively. Gray and white circles indicate true positives (TP).  (B) Combined IgM-
anti-P4/P10 can classify SLE and MCTD patients. The distribution of SLE and MCTD 
patients’ combined IgM anti-P4/P10 predicted values are on the x and y axes, 
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respectively. Black and gray diamonds indicate true positive (TP) samples for SLE and 
MCTD patients, respectively. The crosses represent false negatives (FN) or false 
positives (FP). Predicted values were obtained using binomial logistic regression (BLR) 
with a cut-off of 0.5 (p ≤ 0.05).   
 
Figure 7: Area under the curve analysis reveals the classification power of IgM anti-
P4/P10. Receiver operating characteristic (ROC) curves were generated using peptide 
antigenicities or laboratory tests. The columns in the graph represent the area under the 
curve (AUC) in the y axis for each variable tested. The bars on top of each column 
indicate standard error of the mean. FANA titers, dsDNA, ↑DNA (elevated serum DNA) 
and positive results for RNP, Sm, SSA, SSB and SCL are clinical tests used during SLE 
and MCTD diagnosis. The “IgM anti-P4/P10” indicates the combined IgM anti-P4/P10 
titer while “IgM anti-P4/P10 + ↑DNA” represents the combination of the IgM anti-
P4/P10 ELISA and the elevated DNA assay. The “*” and “**” indicate significant 
differences in classifying SLE and MCTD with p values of ≤ 0.05 and ≤ 0.0001, 
respectively. 
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Figure 5: Contrasting IgM-specific anti-U1 snRNP peptide responses observed in 
SLE and MCTD patients 
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Figure 6: Identification of a two-step ELISA system for classification of SLE, 
MCTD and healthy individuals. 
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Figure 7: Area under the curve analysis reveals the classification power of IgM anti-
P4/P10 
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IV. CHAPTER 3 
 
Developing novel classification rules customized to distinguishing  
between SLE and MCTD patients 
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Introduction 
 Mixed Connective Tissue Disease (MCTD), also known as Sharp’s syndrome, 
was first described in 1972 as an autoimmune disease characterized by high titers of 
antibodies to U1 small nuclear ribonucleoprotein particle (snRNP) (Sharp et al., 1972). 
Since then, the concept of MCTD as a distinct clinical entity has been challenged due to 
the number of common characteristics share mainly with Systemic Lupus Erythematosus 
(SLE) (Aringer et al., 2005; Nowicka-Sauer et al., 2012) and less often with other 
autoimmune syndromes such as Polymyositis (PM), Systemic Sclerosis (SS) and 
Rheumatoid Arthritis (RA) (Mukerji and Hardin, 1993; Egner, 2000; Haustein, 2005). 
Even though the Alarcόn-Segovia criteria is currently the most accepted criteria for 
MCTD, the fact that four different MCTD classification criteria sets currently coexist 
further add to the complexity observed in the diagnosis of these patients (Sharp, 1987; 
Kasukawa et al, 1988; Kahn et al., 1991; Amigues et al., 1996). Furthermore, the initial 
description of MCTD as a benign autoimmune disease (Sharp et al., 1972) most likely 
has jeopardized its relevance as independent identity. Nevertheless, involvement of vital 
organs such as lung and heart in MCTD patients has long been reported by several 
independent investigations (Badui et al., 1984; Smolen and Steiner, 1998; Venables, 
2006; Watanabe et al., 2012; Gunnarsson et al., 2013), however; these findings have not 
caught sufficient attention from the research community. Consequently, new efforts to 
improve current classification methods for MCTD that could facilitate its early diagnosis 
and potential treatment have been limited.          
 Despite the lack of support MCTD has had to be recognized as an independent 
syndrome rather than an SLE like disease, there are a number of serological and clinical 
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characteristics that support the independent nature of these autoimmune disorders. For 
example, typically MCTD patients express elevated autoantibodies targeting U1 small 
nuclear ribonucleoprotein (snRNP) specific proteins known as U1-70K, U1A and U1C 
while those with SLE show anti-Smith (Sm) and anti-dsDNA antibodies (Luyckx et al., 
2005). Moreover, even though some SLE patients develop anti-U1 snRNP response; they 
are able to retain IgM reactivity against these antigens while those with MCTD class 
switch to IgG response instead (Vlachoyiannopoulos et al., 1996; Somarelli et al., 2011; 
Mesa et al., 2013). Likewise, severe renal and central nervous system (CNS) 
manifestations are observed in SLE patients (Zidan et al., 2013) while lung and heart 
malfunctions are frequent in MCTD subjects (Watanabe et al., 2012; Gunnarsson et al., 
2013).  
As a result of contrasting clinical characteristics and specific organ involvement 
reported in SLE and MCTD patients, the recognition of MCTD remains useful in clinical 
practices (Madisson, 2000; Venable 2006; Ortega-Hernandez et al., 2012). Currently 
there is no available method capable of distinguish between these systemic autoimmune 
syndromes given that the two classification criteria sets for SLE and four classification 
rules for MCTD were designed to recognize either of these diseases but not to segregate 
between them (Sharp, 1987; Kasukawa et al, 1988; Kahn et al., 1991; Amigues et al., 
1996; Hochberg et al., 1997; Petri et al., 2012).The aim of this study is to develop novel 
classification criteria specifically designed to segregate between SLE and MCTD 
patients. To do this, 183 clinical and traditional laboratory test variables, 33 experimental 
factors from cytokine and IgM response to antigens as well as six currently used 
classification criteria sets were evaluated in the patient cohort (121 SLE and 41 MCTD). 
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Analysis of the results revealed eight new classification rules for SLE and MCTD 
distinction which are better classifiers than currently existent methods (p ≤ 0.0001). 
Furthermore, these analyses corroborated that the combination of Malar rash and positive 
results for double stranded DNA (dsDNA), FANA titers, elevated creatine proteinase 
kinase (CPK) and IgM reactivity for SmD2amino-aids 14-21 (novel model 1) represents the 
best classification criteria for SLE and MCTD patients with an overall accuracy of 80% 
(p ≤ 0.0001). Additionally, we provide two panels of blood biomarkers that correlate with 
specific organ involvement in either SLE or MCTD patients. Likewise, we highlight a 
number of laboratory tests currently used to assist in the diagnosing of SLE or MCTD but 
lacked classification power for any of these autoimmune syndromes. In summary, this 
research described for the first time classification rules customized for the distinction of 
SLE and MCTD. Despite required validation, these findings could assist in the early 
diagnosis of patients with either SLE or MCTD which in turn may potentially allow the 
development of a specific medical treatment to prevent damage of vital organs frequently 
affected in these patient populations.        
 
Patients and Methods 
Selection of SLE and MCTD patients 
In this study, a total of 165 patients previously diagnosed with either SLE (121 
samples from 98 individuals) or MCTD (41 samples from 27 individuals) were obtained 
following the Florida International University and University of Miami Institutional 
Reviewed Board (IRB) accepted protocols (IRB numbers: 040308-00 as well as 
20030724 and 20040286, respectively). Individuals were diagnosed with SLE by 
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employing the American College of Rheumatology (ACR) criteria for lupus while 
Alarcόn-Segovia criteria were utilized to diagnose those with MCTD (Amigues et al., 
1996; Hochberg et al., 1997). All the individuals included represent well characterized 
patients that have been the subject of previous publications (Maldonado et al., 2006; 
Perkins et al., 2008; Somarelli et al., 2011; Mesa et al., 2013). 
 
Collection of clinical data 
A total of 183 clinical variables were obtained from the 165 patients, when 
available (Appendix 3). These variables include 74 clinical symptoms, 76 traditional 
laboratory tests and 33 experimental blood markers. All the clinical variables were 
recorded on the same date blood and/or urine samples were collected from the patient. 
The traditional laboratory tests refer to standardized commercial laboratory assays 
performed during the diagnosis of patients with SLE or MCTD. Experimental blood 
markers variables include 18 cytokines and IgM reactivity for 15 different peptides 
derived from U1 small nuclear ribonucleoprotein particle (snRNP). Detailed description 
of each of the clinical manifestations as well as normal range and cut off values for 
traditional and experimental laboratory tests are listed in Appendix 3. 
        
Evaluation of classification criteria sets for SLE and MCTD patients 
 Two classification criteria sets available for diagnosing of SLE and four class 
criteria set for MCTD identification were compared regarding their capability to 
segregate patients with either autoimmune syndrome. The classification criteria sets for 
SLE are known as ACR and the recently described Systemic Lupus International 
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Collaborative Clinics (SLICC) (Hochberg et al., 1997; Petri et al., 2012) while those for 
MCTD are named Alarcon-Segovia, Sharp, Kasukawa and Kahn (Sharp, 1987; 
Kasukawa et al, 1988; Kahn et al., 1991; Amigues et al., 1996).  All clinical and 
laboratory tests available from the 183 computerized medical records were employed to 
assess the number of SLE and MCTD subjects from the patient cohorts that could fulfill 
each of the six classification criteria sets. The accuracy, sensitivity and specificity of each 
of the classification criteria sets were estimated using the standard clinical methods.   
 
Construction of reduced classification criteria models for SLE and MCTD segregation 
derived from established class criteria sets 
 The variables composing each of the two classification criteria sets for SLE and 
four class criteria sets for MCTD diagnosis were employed in six independent forward 
Binomial Logistic Regression (BLR) analyses using SPSS (version 18). These analyses 
reveal which combinations of variables improve the segregation of SLE and MCTD when 
compared to each of the individual variables included per classification criteria evaluated 
(p ≤ 0.05). As result, six reduced models were obtained in which each of them correspond 
to a smaller version of each of the six classification criteria considered in the analysis. 
The accuracy, sensitivity and specificity for each of the reduced methods to classify SLE 
and MCTD patients were calculated. Receiving Operating Characteristics (ROC) curves 
were employed to rank the reduced models based in their power to segregate between 
SLE and MCTD patients.       
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Identifying reduced number of variables to develop new classification rule for SLE and 
MCTD discrimination 
 Since this study includes 183 clinical variables but only 165 patients, an initial 
selection of variables was required to maintain stability and robustness of any subsequent 
statistical analysis performed. Knowing that the objective was to develop a new 
classification rule customized for the discrimination of SLE and MCTD patients, all the 
variables showing significant difference between patients with these autoimmune 
disorders were selected (p ≤ 0.05). Likewise, all clinical and laboratory features included 
in each of the reduced classification criteria models were also chosen given that forward 
BLR demonstrate their improved power to discriminate between SLE and MCTD 
patients (p ≤ 0.05). The variables selected to build a new classification rule include 21 
clinical manifestations, 12 traditional laboratory tests and four experimental blood 
markers (Appendix 4). Valvular heart disease, laboratory blood tests for calcium, 
albumin/globulin and creatine kinase as well as the interleukin 17A (IL-17A) 
experimental assay were initially selected but could not be included in the subsequent 
statistical analysis given the reduced number of patients with available values for these 
variables.      
   
Developing novel classification criteria models for SLE and MCTD segregation 
 A total of 37 pre-selected variables which include clinical symptoms as well as 
traditional and experimental laboratory tests (Appendix 4) were considered to develop 
new classification models tailored to segregate between SLE and MCTD patients using 
forward BLR analysis in SPSS (version 18). All 37 variables were considered to 
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construct classification Model 1 while only clinical manifestations and standardized 
laboratory tests (33 variables) were evaluated to build classification Model 2. The 
probability of a patient to be classified as SLE or MCTD based on Model 1 or 2 are 
defined by the following equations, respectively: 
 
Model 1 = logቀ ୔୰	(ௌ௅ா)୔୰	(ெ஼்஽)ቁ = -35 + 54(Malar rash) + 53(dsDNA) - 35(FANA titer)  
   – 55(CPK elevated) + 36 (IgM anti-SmD2 reactivity) 
 
Model 2 = logቀ ୔୰	(ௌ௅ா)୔୰	(ெ஼்஽)ቁ = 19 + 4(Malar rash) - 22(Synovitis) + 3(dsDNA) -     
   24(Scl70)  + 44(ANA) 
 
where each of the models symbolize the log ratio of the combined variables in the SLE 
group divided by that of the MCTD cluster (p ≤ 0.05). The probability of the sample to be 
SLE or MCTD in each model is calculated by plotting the values of each of the 
characteristics listed within parenthesis in each the independent equations. For each of 
the models, a probability >0.5 indicates the patients belong to the SLE group while a 
probability <0.5 classify the patient as MCTD.   
Statistical analysis  
 Significant differences between SLE and MCTD patients for each of the 187 
clinical variables included in this study were determined by Chi (X) square or 
independent sample T test in SPSS (version 18) when the value was nominal or 
numerical, respectively (p ≤ 0.05). Correlations between laboratory tests and clinical 
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manifestations observed in either SLE or MCTD patients were determined by T-
test/ANOVA with repeated measurements within patients for test with numerical values 
while a generalized linear mixed model was applied to assays with binary values (p ≤ 
0.05). The resulting p-values for each of the correlations were used to construct a 
heatmap for each autoimmune syndrome in R where significant correlations before and 
after Bonferroni correction as well as variables with no correlation are color coded in 
white, blue and red, respectively. Alopecia, swelling of neck lymph nodes, rheumatoid 
nodule, hemolytic anemia, avascular necrosis, pulmonary vascular lesions, renal clot, 
renal arterial stenosis, chorea and phychosis were not included during the correlation 
analysis because insufficient sample size and/or lack of sufficient variability in SLE 
and/or MCTD cohorts.  Receiving Operating Characteristic (ROC) curves were 
performed in SPSS (version 18) to corroborate and compare classification power of each 
of the models resulting from forward BLR (p ≤ 0.05).       
  
Results 
Contrasting clinical and serological features are exhibited by SLE and MCTD patients  
 Each of the 183 clinical variables included in this research (Appendix 3) were 
evaluated to assess significant differences between SLE and MCTD populations. We 
identified 35 variables that significantly differ between these autoimmune diseases  
including clinical symptoms related to skin, muscle , kidney  and heart  tissues as well as 
a 18 serological assays (p ≤ 0.05) (Figure 8). Interestingly, the skin derived variables 
(Raynaud’s Malar and Discoid rashes) tend to be higher in SLE than MCTD patients (p ≤ 
0.05). Likewise, the study of muscle features showed that SLE patients appear to have 
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greater inflammation of the joints and extremities while MCTD individuals exhibit 
prevalence of myositis and muscle weakness (p ≤ 0.05). As expected, renal disease and 
renal hematuria are elevated in SLE but not MCTD patients (p ≤ 0.05). Additionally, 
myocardial infarction is elevated in MCTD patients while valvular heart disease seems to 
be more frequent in SLE individuals (p ≤ 0.05). Evaluation of the serological assays 
revealed that with the exception of creatine phosphate kinase and positive antibodies for 
topoisomerase (Scl-70 +), all the traditional laboratory tests were higher in the SLE 
population when compared to the MCTD group (p ≤ 0.05). Similarly, all the experimental 
tests which include identification of interleukin 17A and IgM reactivity for U1A, SmD1 
and SmD2 are elevated only in SLE but not MCTD individuals (p ≤ 0.05). Consequently, 
this analysis showed that SLE and MCTD patients exhibit unique clinical manifestations 
and molecular markers (p ≤ 0.05). 
 
Molecular markers associations with unique tissue damage are specific to either SLE or 
MCTD patients 
         Each of the laboratory tests analyzed in this study was individually correlated with 
clinical symptoms presented in patients diagnosed with SLE or MCTD (Figures 2 and 3). 
The resulting p-value heatmap uncovered the SLE cohort seven clinical manifestations 
significantly associated with IL33 (oral ulcers, leukopenia and lymphopenia), IL12p40 
(telangiectasia and joints deformity), BAFF (Thrombosis) and positive protein in urine 
(renal disease) (p ≤ 0.05) (Table 5 and Figure 9).   Different significant correlations were 
detected in the MCTD population where seven molecular markers were significantly 
associated with nasal ulcers (BAFF), oral ulcers (IL33), anemia (C3 and C4 level as well 
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as IgM and IgG rheumatoid factor ELISA titer) and pleuritis (IL17A) (p ≤ 0.05) (Table 5 
and Figure 10). It is noteworthy that IL33 correlates with oral ulcers equally in SLE and 
MCTD (p ≤ 0.05). Interestingly, 44% (4/9) of the biomarkers that show significant 
correlations with specific clinical symptoms correspond to new experimental blood 
antigens that showed reactivity in SLE and/or MCTD patients.  In this way, the p-value 
heatmaps resulting from correlation analysis suggest that correlations of molecular 
markers and clinical manifestations are unique to either SLE or MCTD patients (p ≤ 
0.05). 
 
Classification criteria sets are not designed for segregating SLE and MCTD patients 
Each of the six criteria sets for the classification of either SLE or MCTD was 
applied to the patient cohorts to evaluate their capacity to segregate between these 
autoimmune syndromes (Table 6). These analyses revealed that there is virtually no 
difference in the accuracy of the new (Systemic Lupus International Collaborating 
Clinics (SLICC)) and old (ACR) SLE classification criteria sets (p ≤ 0.05) (Table 6). This 
is an important observation considering SLICC is composed by 25 additional variables 
that are not listed in the ACR class criteria (Hochberg et al., 1997; Petri et al., 2012). 
Specifically, SLICC and ACR showed elevated sensitivity (93.26% and 85.39%, 
respectively) but both have deficient specificity (13.33, and 24.44%, respectively) (Table 
6). When evaluating all the MCTD class criteria sets, the Alarcόn-Segovia showed the 
best accuracy (72.39%) at discriminating between SLE and MCTD even though Sharp, 
Kasukawa and Kahn class criteria sets also exhibited significant segregation between the 
two autoimmune disorders (p ≤ 0.05) (Table 6). In contrast to SLICC and ACR 
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classification criteria, the Alarcόn-Segovia exhibits moderate sensitivity (64.44%) and 
specificity (76.40%) in distinguishing between MCTD and SLE patients (p ≤ 0.05) (Table 
6). Taken all these together, the data showed that the six established methods for the 
classification of SLE (ACR and SLICC) and MCTD (Alarcόn-Segovia, Sharp, Kasukawa 
and Kahn) lack power to segregate patients diagnosed with either these syndromes.               
       
Regression analysis of existent classification criteria sets uncover essential factors 
required for SLE and MCTD segregation 
Six independent forward BLR analyses with variables corresponding to those listed in 
each of the six classification criteria were performed to construct six reduced models. 
Evaluation of the reduced models exposed 6 combinations from 18 essential features with 
significant power to differentiate between SLE and MCTD patients (Table 7). 
Comparison of all six reduced models reveals that the reduced Kasukawa (rKasukawa) 
shows the highest accuracy (85.5%) at segregating between these autoimmune syndromes 
which power is derived by the combination of Raynaud’s phenomenon, Malar rash, 
adenopathies, sclerodactyly and muscle weakness (p ≤ 0.05) (Table 7). Specifically, the 
rKasukawa not only showed superior sensitivity (75%) and specificity (90.5%) when 
compared to the other five reduced models but seems a better classifier than the Alarcόn-
Segovia classification criteria to discriminate between SLE and MCTD patients (Table 
7). Indeed, all the reduced models are better classifiers for SLE and MCTD patients when 
compared to their corresponding complete class criteria (Tables 2 and 3). Consequently, 
the forward BLR revealed four groups composed by combination of 18 core variables 
with the capacity to segregate between SLE and MCTD (p ≤ 0.05).  
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ROC curves confirmed the classification power of reduced class criteria models 
A total of six individual ROC curves analyses were performed to confirm the 
segregation power of the variable per criteria set when compared to the corresponding 
complete classification criteria (Table 6) as well as proposed reduced models (Table 7). 
As expected, the ROC analysis confirmed that all reduced models are a better classifier 
for these autoimmune syndromes than any of the complete class criteria or any variable 
included in them (p ≤ 0.0001) (Figure 11). Likewise, the analysis revealed that two 
laboratory tests previously identified by BLR (positive dsDNA and RNP in Table 7) have 
individual power to distinguish between SLE and MCTD patients (p ≤ 0.05) (Figure 11). 
Also, eight of the clinical symptoms predicted by BLR (synovitis, Malar rash, non-
erosive arthritis, acrosclerosis, Raynaud’s, esophageal hypomotility, sclerodactitily and 
muscle weakness in Table 7) showed to have individual power to segregate between SLE 
and MCTD (p ≤ 0.05) (Figure 11). In addition, the ROC analysis uncovered that swollen 
hands and negative laboratory results for Sm (Sm-) each have independent capability to 
separate SLE from MCTD patients (p ≤ 0.05) (Figure 11). Therefore, the ROC analysis 
exposed ability of swollen hands and Sm- results in segregating between these 
autoimmune disorders as well as confirmed the power of 10 out of the 18 variables 
identified by BLR in differentiating between SLE and MCTD patients (p ≤ 0.05).     
 
Construction of novel class criteria sets to assist diagnosing of SLE and MCTD 
 A total of 37 pre-selected variables (Appendix 4) were employed in forward BLR 
analysis to develop new predicted models tailored specifically for SLE and MCTD 
classification. When considering experimental and traditional laboratory assays as well as 
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clinical symptoms, the analysis revealed that the combination of Malar rash, positive 
results for dsDNA and FANA titers, elevated creatine phosphate kinase (CPK) and IgM 
anti-SmD2amino-acids 14-21 reactivity (referred to as Model 1) exhibits an overall accuracy of 
80% in discriminating between SLE and MCTD patients with sensitivity and specificity 
of 92% and 74%, respectively (p ≤ 0.0001) (Table 8). A separate forward BLR analysis 
was performed utilizing only traditional laboratory tests and clinical manifestations from 
patients with either SLE or MCTD. The data confirmed that the combination of Malar 
rash, synovitis as positive results for dsDNA, topoisomerase (Scl70) and anti-nuclear 
assay (ANA) (named Model 2) showed a 74% accuracy at discerning between these two 
autoimmune syndromes with 83% sensitivity and 69% specificity (p ≤ 0.0001) (Table 8). 
In summary, the BLR analysis uncovered two novel class criteria sets (Models 1 and 2) 
which were custom built for discriminating between SLE and MCTD patients (p ≤ 
0.0001).   
 
Model 1 represents the best classification rule to discern between SLE and MCTD 
patients 
 Novel proposed classification Models 1 and 2 (Table 8) were included in ROC 
curves analysis along with each of the classification criteria for SLE and MCTD (Table 
6) and their corresponding reduced models (Table 7) to compare their classification 
power for SLE and MCTD patients. The analysis confirmed that Model 1 exhibits the 
highest capacity to discern between SLE and MCTD with AUC = 0.930 (p ≤ 0.0001) 
(Figure 12). Likewise, rKasukawa model, rACR model, rSharp model, Model 2, rSLICC 
model, rAlarcon-Segovia model and Sharp classification criteria occupy the second to 
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eight place in having power to classify SLE and MCTD patients (p ≤ 0.05) (Figure 12). 
The rKahn model and the rest of the classification criteria sets (Kasukawa, Alarcon-
Segovia, Kahn, ACR and SLICC) were unable to segregate patients diagnosed with any 
of these autoimmune syndromes (Figure 12). Therefore, ROC curves analysis confirmed 
that the combination of variables included in Model 1 are the best classification rule for 
SLE and MCTD patients when compared to Model 2, all  six classification criteria sets 
available for these autoimmune disorders as well as their corresponding reduced models 
(p ≤ 0.0001).         
 
Discussion 
 Since its initial description by Sharp et al. (1972), the recognition of MCTD as an 
unique disease has been constantly challenged, mainly due to the number of overlapping 
characteristics shared by patients diagnosed with SLE (Aringer et al., 2005; Nowicka-
Sauer et al., 2012). Currently, in cases where the concept of MCTD is acknowledged, it is 
often portrayed as a subset of SLE patients with good prognosis despite exhibiting 
features listed in SLE and MCTD classification criteria sets and prevalence of lung and 
heart problems (Badui et al., 1984; Smolen and Steiner, 1998; Venables, 2006; Watanabe 
et al., 2012; Gunnarsson et al., 2013; Bertsias et al., 2013). The reported contrasting 
organs involvement in patients with diagnosis of MCTD (lung and heart) when compared 
to those with SLE (kidney and CNS) provides evidence of the clinical relevance of the 
MCTD concept to prevent and/or treat organ malfunction in these autoimmune 
syndromes, regardless if MCTD is recognized as a separate illness or a SLE subtype. 
Given that available classification criteria sets were developed to identify either SLE or 
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MCTD subjects but not to segregate between them, it seems imperative to design 
classification rules specifically tailored to discriminate SLE and MCTD patients since 
early class group identification could influence the type of medical plan developed to 
impede or reduce organ damage, thus potentially improving the patient’s prognosis. This 
investigation provides, for the first time, eight different classification rules strategically 
derived for the segregation of SLE and MCTD patients. Analysis of the resulting data 
confirmed that all eight proposed models exhibit a higher power to correctly identify SLE 
or MCTD patients than any other available class criteria set (p ≤ 0.0001). Despite a 
required validation step, the proposed models highlight clinical and molecular features 
with power to segregate SLE and MCTD subjects while providing additional evidence to 
support the independent etiology of these autoimmune syndromes. 
In congruency with previous reports (Vlachoyiannopoulos et al., 1996; Luyckx et 
al., 2005; Somarelli et al., 2011; Watanabe et al., 2012; Gunnarsson et al., 2013; Mesa et 
al., 2013; Zidan et al., 2013), the analysis of 187 medical records documented for SLE 
and MCTD patients revealed that 35 clinical manifestations and molecular features are 
significantly different in the two disease states (Figure 8). The prevalence of skin rashes 
in SLE while myositis and muscle weakness was presented in MCTD was expected since 
these are typical clinical manifestation associated with each of these autoimmune 
illnesses (Uthman et al., 1996; Belibou et al., 2012; Szodoray et al., 2012). Like others 
(Watanabe et al., 2012; Gunnarsson et al., 2013; Zidan et al., 2013), the data showed that 
specific organ malfunction was involved with each of these syndromes where renal 
disease was elevated in SLE cohort while myocardial infarction was more frequently in 
the MCTD population (p ≤ 0.002). Additionally, the correlation analyses support the idea 
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that SLE and MCTD are indeed separate disorders given that unique correlations of 
molecular markers and clinical symptoms are observed in either SLE or MCTD cohorts 
(Figures 2 and 3). An interesting association revealed was between IL17A and pleuritis 
observed only in MCTD but not SLE subjects (Table 5). In addition to representing a 
novel potential blood biomarker, the association of IL17A and pleuritis might indicate 
pleural inflammation related to bacterial infections as has been recently reported 
(Monguilhott Dalmarco et al., 2011; Kollintza et al., 2013). It is noteworthy to mention 
that the frequency of lung disease in the SLE and MCTD cohorts does not differ (44% 
and 48% respectively). Given that some studies have reported the predominance of lung 
disease in MCTD patients (Sasaki et al., 2011; Gunnarsson et al., 2012) while others have 
uncovered that lung malfunction in these patients is lower than expected (Gunnarsson et 
al., 2013), these results suggest that additional investigations encompassing bigger 
MCTD samples and inclusion of other autoimmune syndromes are required to assess if 
lung disease should be considered as a target organ during the diagnosis and treatment of 
MCTD. Consequently, the data provide grounds to suggest that new classification rules 
customized for SLE and MCTD segregation should be developed to prevent and/or 
reduce organ involvements in these patients.  
The evaluation of ACR, SLICC, Alarcόn-Segovia, Sharp, Kasukawa, and Kahn 
criteria sets revealed the average capability of segregating SLE and MCTD patients 
(Table 6). Specifically, the misclassification rate of patients using any of these methods 
ranges from 36% to 87% for MCTD subjects (16/45 and 39/45 MCTD incorrectly 
grouped by Alarcόn-Segovia and SLICC, respectively) while varies from 7% to 56% for 
SLE (6/89 and 48/85 SLE mistakenly clustered by SLICC and Kasukawa, respectively). 
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This deficiency of classification power was expected given that the inclusion of MCTD 
patients was not recognized during the development of SLE classification criteria sets 
(Tan et al., 1982; Hochberg et al., 1997; Petri et al., 2012). By contrast, patients 
diagnosed with SLE and other autoimmune syndromes were included during the 
production of each of the four classification criteria sets for MCTD (Amigues et al., 
1996). Nevertheless, these studies did not included well characterized MCTD cases and 
rather choose the presence of positive anti-U1 snRNP antibodies as patient inclusion 
criteria despite knowing these antigens elicit a response in SLE and MCTD subjects 
(Amigues et al., 1996; Sato et al., 2010; Nagai et al., 2012, Mesa et al., 2013).  
Consequently, these findings provide evidence to suggest that currently available SLE 
and MCTD classification criteria sets do not exhibit sufficient power to correctly identify 
SLE or MCTD patients (Table 6) (Figure 11). 
The regression analysis identified eight different novel classification rules (Tables 
3 and 4) which exhibit significantly higher capability to segregate SLE and MCTD 
patients than any other classification criteria sets available (p ≤ 0.05) (Figure 12). 
Particularly, Model 1 composed by the presence of Malar rash, elevated CPK and 
positive results for dsDNA, FANA and IgM anti-SmD (Table 8), represents the best 
classifier to identify SLE and MCTD patients with an significant AUC of 0.930 (p ≤ 
0.0001) (Figure 12). The segregation power of the combination of variables in Model 1 
was predicted given that, with the exception of elevated CPK; all the other clinical 
characteristics and lab tests have been repetitively reported elevated in SLE patients but 
reduced in MCTD subjects (Vlachoyiannopoulos et al., 1996; Luyckx et al., 2005; 
Somarelli et al., 2011; Mesa et al., 2013). The misclassification rate of proposed Model 1 
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attains 8% for MCTD patients (2/24 incorrectly clustered) and 26% for SLE subjects 
(11/42 falsely grouped). In this way, the overall classification power for SLE and MCTD 
shown by Model 1 is significantly improved when contrasted with existent validated 
classification criteria sets (p ≤ 0.0001) (Figure 12). Additionally, the results revealed that 
rKasukawa, rACR, rSharp, Model 2, rSLICC and rAlarcόn-Segovia follow Model 1 in 
their power to segregate between SLE and MCTD patients (p ≤ 0.05) (Figure 12). The 
ROC curves confirmed that Sharp classification criteria exhibit significant ability to 
discern between these autoimmune syndromes however the average AUC (0.684) 
highlights the average power of this criteria set (p ≤ 0.05) (Figure 12).  
Taking all of this together, this study shows evidence to support the relevance of 
recognizing the MCTD concept while providing, for the first time, eight different 
classification rules tailored for the specific classification of SLE and MCTD patients. 
Given that these results and others have identified specific organ involvement in either 
SLE or MCTD patients (Figure 8) (Vlachoyiannopoulos et al., 1996; Luyckx et al., 2005; 
Watanabe et al., 2012; Gunnarsson et al., 2013; Mesa et al., 2013; Zidan et al., 2013), it 
highlights the clinical value of MCTD diagnosis given that the type of medical regime 
delivered to a patient will rely on the potential development of specific organ(s) 
malfunction. Aware of the lack of methods designed to segregate between these 
autoimmune disorders (Table 6 and Figure 11), we described eight different novel 
classification rules (Tables 3 and 4) from which Model 1 (derived by the combination of 
Malar rash, elevated CPK and positive results for dsDNA, FANA and IgM anti-SmD) 
represents the best classifier from those evaluated with a power of 93% to distinguish 
between SLE and MCTD patients (Figure 12). Noteworthy the limitations and the need 
84 
 
for a validation step of the current findings, we believe that the time has come to 
recognize the clinical relevance of the MCTD concept to prevent and/or treat organ 
malfunction. Consequently, the proposed classification rules presented in this research 
pioneers the efforts to attain the development of new consensus criteria custom made for 
segregating between SLE and MCTD patients. 
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Table 5: List of molecular markers associated with clinical manifestations in SLE 
and MCTD patients 
 
 
 
 
 
 
 
 
 
 
Tissue
affected
Molecular 
markers SLE MCTD
Skin
BAFF ø Nasal ulcers
IL33 Oral ulcers Oral ulcers
Joints IL12p40
Telangiectasia ø
Deformity ø
Blood
C3 level ø
Anemia
C4 level ø
IgM RF ELISA titer ø
IgG RF ELISA titer ø
IL33
Leukopenia ø
Lymphonia ø
BAFF Thrombosis ø
Heart IL17A - Pleuritis
Kidney Urine protein + Renal disease ø
Experimental molecular markers are in italics while traditional lab tests are not. All the markers listed
are associated with each of the clinical symptoms with a p-value ≤ 0.05 and Bonferroni correction. The
empty symbol (ø) represents no significant correlation determined with p ≤ 0.05 after Bonferrori
correction. Interlukins are denoted as follow: IL33, IL12p40, BAFF and IL17A). “RF” stands for
rheumatoid factor while urine protein + corresponds to protein detection in urine samples.
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Table 6: Evaluating SLE and MCTD classification criteria sets  in patient cohort 
included in the present study 
 
 
 
 
 
 
 
 
 
 
 
 
Classification 
criteria sets
SLE MCTD
p-value
Correctly
classified
Incorrectly
classified
Correctly
classified
Incorrectly
classified
S
L
E
SLICC 83 6 6 39 0.207
ACR 76 13 11 34 0.161
M
C
T
D
Alarcόn-Segovia 68 21 29 16 <0.0001
Sharp 48 41 37 8 <0.0001
Kasukawa 37 48 42 3 <0.0001
Kahn 82 7 11 34 0.008
SLICC and ACR stands for Systemic Lupus International Collaborating Clinics and American College of Rheumatology,
respectively. The analysis were performed in SPSS (version 18) and included 89 SLE patients and 45 MCTD individuals.
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Table 7: Description of reduced models for each SLE and MCTD classification 
criteria 
 
 
 
 
 
 
 
 
 
 
Reduced models for
each classification  
criteria
Accuracy p-value Features included in the reduced models
S
L
E
rSLICC 79.6% <0.0001 Discoid rash,  joint synovitis, leukopenia, ANA+,  dsDNA+, Sm+ and phospholipid +
rACR 74.4% <0.0001 dsDNA+, hemolytic anemia, Malar rashand Non-erosive arthritis 
M
C
T
D
rAlarcόn-Segovia 74.2% <0.0001 Synovitis and acrosclerosis
rSharp 78.4% <0.0001 Severe myositis,  Raynaud’s or esophageal hypomotility, RNP+, Sm+
rKasukawa 85.5% <0.0001 Raynaud’s, adenopathies, Malar rash, sclerodactyly and muscle weakness 
rKahn 69.7% <0.0001 Raynaud’s and synovitis
SLICC and ACR stands for Systemic Lupus International Collaborating Clinics and American College of Rheumatology,
respectively. Anti Nuclear Antibody positive (ANA+) as well as positive antibody detection of double stranded DNA (dsDNA+),
Smith protein (Sm+) phospholipid (phospholipid +) and Ribo-Nucleo-protein (RNP+) are indicated. The analysis were performed
using the binomial logistic regression (BLR) function in SPSS (version 18) and included 89 SLE patients and 45 MCTD
individuals.
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Table 8: Description of novel models for segregation of SLE and MCTD patients 
 
 
 
 
 
Proposed
models
Features included 
in each model Cut-off Accuracy p-value
Model 1
Malar rash, dsDNA+, FANA titers,
elevated CPK and IgM reactivity for 
SmD2amino-acids 14-21. 
0.42 80.30% <0.0001
Model 2 Malar rash, synovitis, dsDNA+, Scl70+, ANA+ 0.28 73.64% <0.0001
The models were obtained using binomial logistic regression (BLR) function in SPSS (version 18) when clinical
variables as well as traditional and experimental laboratory tests from SLE and MCTD patients were considered
(Appendix 4). Model 1 was built using experimental and traditional variables from 42 SLE and 24 MCTD patients
while only traditional variables derived from 75 SLE and 35 MCTD patients were considered for Model 2. Values under
the cut off points will be classified as SLE while those above it will be identified as MCTD. Positive antibody detection
of double stranded DNA (dsDNA+), toposiomerase (Scl70+) and Anti Nuclear Antibody positive (ANA+) are indicated.
The experimental variable is denoted in italics.
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Figure legends 
Figure 8: SLE and MCTD differ in the prevalence of clinical characteristics and 
molecular factors. In each graph, the inner circle represents the MCTD cohort while the 
outside circle consists of the SLE population. Positive and negative values for each of the 
variables are represented by green and red, respectively. History of proximal muscle 
weakness, observed proximal muscle weakness, observed joints swelling, symmetric 
joints swelling, low extremity swelling are denoted by “H prox muscle weakness”, “O 
prox muscle weakness”, “O joints swelling”, “S joints swelling” and “L extremity 
swelling”, respectively. Positive laboratory tests for ribonucleoprotein (RNP), Smith 
proteins (Sm), double stranded DNA (dsDNA), Fluorescent Antinuclear Antibodies 
(FANA), anti-La antibodies (SSP) and topoisomerase (Scl) are indicated with “+”. 
Experimental antigens as opposed to traditional laboratory tests are in italics. 
 
Figure 9: Proposed biomarker panel for clinical manifestations observed in SLE 
patients. In the plot, the clinical symptoms and laboratory tests are on the “x” and “y” 
axis, respectively. The white, blue and red boxes indicate significant correlations, 
significant correlations after Bonferroni corrections and no correlations, respectively (p ≤ 
0.05). Hand swelling, proximal scleroderma, any heart clot, valvular heart diseases, 
pulmonary hypertension, pulmonary fibrosis, gastric reflux, lymph nodes swelling, 
morning stiffness, myocard infarction and interlukin receptor BAFFR were initially 
considered in the analysis but not included due to the reduced sample size for each of 
these variables.       
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Figure 10:  Specific blood markers correlate with clinical symptoms in MCTD 
patients. Laboratory tests performed in MCTD subjects are displayed in the “y” axis 
while clinical manifestations exhibit in this patient population are on the “x” axis. The 
white, blue and red boxes indicate significant correlations, significant correlations after 
Bonferroni corrections and no correlations, respectively (p ≤ 0.05). Renal proteinuria, 
hematuria and cell cast, stroke, venous heart clot, lung disease, synovitis, symmetric 
swelling of the joints, observed proximal muscle weakness and calcinosis were initially 
considered for the correlations but not included in the final analyses given the reduced 
sample size available in the MCTD cohort for these variables.    
 
Figure 11: Reduced models for each SLE and MCTD classification criteria exhibit 
better power in discriminating between SLE and MCTD patients. Each of the 
reduced models were obtained by applying binomial logistic regression (BLR) in SPSS 
(version 18) when all the variables per classification criteria were considered in SLE (n = 
89) and MCTD (n = 45) patients. The Systemic Lupus International Collaborating Clinics 
(SLICC) and American College of Rheumatology (ACR) classification criteria sets for 
SLE diagnosis are denoted with A and B, respectively. The Alarcόn-Segovia (C), Sharp 
(D), Kasukawa (E) and Kahn (F) represent the classification criteria sets for diagnosing 
MCTD patients. In each plot, the area under the curve (AUC) from Receiving Operating 
Characteristics (ROC) curves are on the y axis. Each of the columns represent 
characteristics and the reduced model included per classification criteria. The lines on top 
of each column are standard error. Significant difference between SLE and MCTD 
91 
 
patients with p-values ≤ 0.05, ≤ 0.005 and ≤ 0.0001 are denoted with “*”, “**” and 
“***”, respectively.   
 
Figure 12: Proposed Model 1 exhibits the highest discrimination power in 
identifying SLE and MCTD patients. The x axis includes the classification criteria for 
SLE and MCTD, their correspondent reduced models as well as the new proposed models 
(Model 1 and Model 2) for segregation of patients with these autoimmune syndromes. 
The y axis represents the area under the curve (AUC) resulting from the Receiving 
Operating Characteristics (ROC) curves analysis. Variables with significant power to 
differentiate between SLE and MCTD with p-values of 0.05, 0.005 and ≤ 0.0001 are 
indicated with “*”, “**” and “***”, respectively.    
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Figure 8: SLE and MCTD differ in the prevalence of clinical characteristics and 
molecular factors 
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Figure 9: Proposed biomarker panel for clinical manifestations observed in SLE 
patients 
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Figure 10: Specific blood markers correlate with clinical symptoms in MCTD 
patients 
 
 
 
 
 
 
 
95 
 
Figure 11: Reduced models for each SLE and MCTD classification criteria exhibit 
better power in discriminating between SLE and MCTD patients 
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Figure 12: Proposed Model 1 exhibits the highest discrimination power in 
identifying SLE and MCTD patients 
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V. CONCLUSIONS 
 The recognition of MCTD as a separate disorder from SLE has remained 
debatable since its initial description in 1972 (Sharp et al., 1972; Aringer et al., 2005; 
Nowicka-Sauer et al., 2012). Nevertheless, the clinical relevance of the MCTD concept to 
identify individuals with different organ malfunction from patients that fulfill the SLE 
classification criteria has been documented (Badui et al., 1984; Smolen and Steiner, 
1998; Venables, 2006; Watanabe et al., 2012; Gunnarsson et al., 2013; Bertsias et al., 
2013). This investigation provides clinical and molecular evidence to support the 
independent etiology of SLE and MCTD. The experimental approach suggests that 
models resulting from the IgM anti-U1 snRNP titers could be considered as a potential 
blood biomarkers capable of differentiating SLE from MCTD patients as well as 
molecular indicators for lung and kidney disease in patients suffering from any of these 
disorders (p ≤ 0.005). Likewise, derivation of the data analysis resulted in the description 
of novel classification rules for SLE and MCTD with significant improved classification 
power when compared to available methods (p ≤ 0.005). Even knowing that these 
findings must be validated and recognizing the limitations of the approached utilized in 
this research, the results strongly suggest that the described biomarkers and classification 
criteria sets might have clinical relevance during the accurate identification of MCTD 
therefore potentially improving patients’ prognosis.               
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APPENDIX 1 
Protocol for generating a 3D protein structure and applying a heat scale to residues 
of interest 
This protocol assumes that the amino acid sequence of a protein of interest is available. 
 
Generating a heat map scale 
The goal for generating a heat map scale is to pick one group as a baseline and then 
compare how far above or below that baseline some other group performs. The resulting 
deviation should range from 0 to 1. In general, one picks the control group (i.e. healthy 
subjects) as the baseline. For a four color heat scale of blue to green to yellow to red, with 
blue being least intense and red being most intense, the following procedure can be used.  
1. For each value measured, calculate deviation by the test group from the control 
group using the formula: 
Deviation=0.5+ Test-Control 
2. Calculate the appropriate RGB values for the deviation. 
a. In Excel, place the value for Deviation in cell B2. 
b. To calculate the Red RGB value, place the following code in cell C2: 
• =IF(B2>0.67,255,IF(B2>0.33,255*(3*B2-FLOOR(3*B2,1)),0)) 
c. To calculate the Green RGB value, place the following code in cell D2: 
• =IF(B2>0.67,-255*(3*B2-
FLOOR(3*B2,1))+255,IF(B2>0.33,255,255*(3*B2-
FLOOR(3*B2,1)))) 
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d. To calculate the Blue RGB value, place the following code in cell E2: 
• =IF(B2>0.33,0,-255*(B2*3-FLOOR(B2*3,1))+255) 
3. Use the resulting RGB values as custom colors in some other application. An 
example is Case 1 step 5 below. 
 
Generating 3D structures 
In terms of an experimentally determined 3D structure of the protein, there are three 
cases that are addressed: (1) no such 3D structure is available; (2) a partial structure is 
available; or (3) a complete structure is available. 
 
Case 1 
1. Submit the amino acid sequence to the I-TASSER protein structure prediction 
server to generate 3D structures of your protein. The server is located at: 
http://zhanglab.ccmb.med.umich.edu/I-TASSER/. 
2. Download and install PyMOL to visualize the predicted structures. It can be 
obtained at: http://www.pymol.org/. 
3. Open the I-TASSER model of interest (usually the one with the highest C-score) 
in PyMOL. 
4. Define your residues of interest using the select command. 
• Example, to define residues 10 through 20 by the name p1, at the 
PyMOL> prompt type:  
• select p1, resi 10–20 
 Define your custom colors from the heat map scale using the set_color command. 
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• Example, to define a custom color with RGB values of R=127, G=255, 
B=212, type:  
• set_color p1_color = [127, 255, 212] 
 Assign your custom colors to your residues of interest. 
• For the example residues and color above, type: 
• color p1_color, p1 
 Repeat steps 4 through 6 for each set of residues of interest. 
 Choose how you would like your structure represented. From the PyMOL viewer 
next to “all”, click S for Show, then “as” and choose either lines, sticks, ribbon, or 
cartoon. 
 To change the background color to white, type: 
• bg_color white 
 Orient the structure as desired, or click the Orient button in the PyMOL console. 
If planning to create an animation, be sure to leave sufficient white space around the 
structure. 
 To save a high quality image of the structure, type: 
• ray 
• Click on File->Save Image As->PNG… and select your filename 
 For a rotated image, type: 
• rotate y, 180 
• Repeat step 11 
 Open your image in a graphics package (for example, Photoshop) to add labels. 
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 To create an animated GIF of your structure, first install ImageMagick. It can be 
obtained at: http://www.imagemagick.org/script/index.php.  
 Create a series of still images to serve as frames for your animation. From the 
PyMOL prompt, type: 
• mset 1 x60 
• util.mrock 1,60,180 
• set ray_trace_frames=1 
• mpng frame 
 Copy your frames to a temporary folder and open a command prompt. Type: 
• convert -delay 1 -loop 0 frame*.png animated.gif 
 
Case 2 
1. Follow steps 1 and 2 as in Case 1. 
2. Compare your predicted structures to your experimentally determined structure in 
PyMOL by superposition. 
a. Open your experimentally determined structure and your I-TASSER models in 
PyMOL. 
b. For each comparison, where model is the name of your predicted structure and 
experimental is the name of your experimentally determined structure, type: 
c. super model, experimental 
d. Find the best ratio of retained atoms to RMS value from the final line of output. 
 Using only the best superposition, follow steps 4 through 15 as in Case 1. 
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Case 3 
1. Follow steps 2 and steps 4 through 15 as in Case 1. 
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APPENDIX 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variables 
IgM reactivity IgG reactivity 
AUC SE p value AUC SE p value 
P1 .562 .055 .286 .863 .036 <.0001 
P2 .570 .057 .227 .613 .050 .053 
P3 .567 .061 .251 .796 .043 <.0001 
P4 .522 .059 .710 .925 .024 <.0001 
P5 .575 .058 .197 .933 .029 <.0001 
P6 .579 .058 .173 .842 .037 <.0001 
P7 .558 .059 .321 .787 .044 <.0001 
P8 .598 .060 .091 .857 .039 <.0001 
P9 .508 .060 .890 .653 .047 .008 
P10 .547 .059 .424 .867 .035 <.0001 
P11 .509 .058 .874 .817 .041 <.0001 
P12 .517 .056 .773 .850 .040 <.0001 
P13 .560 .056 .305 .804 .046 <.0001 
P14 .613 .053 .052 .895 .033 <.0001 
P15 .532 .060 .583 .849 .043 <.0001 
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APPENDIX 2, continuation 
 
Variables 
IgM reactivity IgG reactivity 
AUC SE p value AUC SE p value 
P1 .631 .053 .018 .587 .054 .119 
P2 .547 .053 .402 .534 .056 .540 
P3 .551 .054 .358 .536 .054 .517 
P4 .537 .054 .500 .505 .056 .922 
P5 .570 .053 .210 .549 .054 .374 
P6 .581 .053 .147 .510 .055 .852 
P7 .561 .054 .269 .516 .054 .780 
P8 .548 .054 .387 .527 .057 .624 
P9 .577 .053 .164 .538 .053 .498 
P10 .585 .052 .124 .528 .056 .745 
P11 .574 .052 .185 .502 .056 .978 
P12 .584 .052 .128 .536 .056 .512 
P13 .610 .051 .048 .569 .055 .214 
P14 .600 .052 .072 .556 .055 .316 
P15 .605 .053 .060 .545 .056 .422 
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APPENDIX 2, continuation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variables AUC SE p value 
IgM P1 OD .664 .061 .016 
IgM P13 OD .618 .063 .084 
IgM P4 OD + IgM P10 OD .731 .057 .001 
FANA titters .553 .066 .437 
RNP positive .589 .063 .189 
Sm positive .638 .065 .043 
SSA positive .554 .068 .428 
SSB positive .561 .066 .374 
SCL positive .565 .070 .338 
DNA elevated .665 .065 .023 
ds DNA titters .605 .062 .123 
IgM P4/P10 OD + DNA elevated .798 .052 <.0001 
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APPENDIX 3 
 
Variable Definition 
Sk
in
 
Telangiectasia Skin telengectasia observed 
Nasal ulcers Skin nasal ulcers observed 
Oral ulcers Skin oral ulcers observed 
Raynaud 
Raynaud: a pattern of color changes in the fingers as 
follows: pale/white followed by blue then red when the 
hands are warmed; color changes are usually preceded 
by  exposure to cold or emotional upset 
Skin hand swelling history Hand swelling by history 
Skin hand swelling observed Hand swelling observed 
Sclerodactyly Skin sclerodacytyl / acrosclerosis  
Pitting Skin digital pitting 
Alopecia Skin alopecia-patchy or generalized 
Malar  rash Skin malar rash- fixed erythema, flat or raised, over the malar eminences, tending to spare the solabial folds 
Discoid rash 
Skin discoid rash- erythematous raised patches with 
adherent keratotic scaling and follicular plugging. 
Atrophic scaring seen in older lesions 
Skin rash Skin rash other by history or exam 
Photosensitivity Skin photosensitivity- skin rash as a resulf of unusual reaction to sunlight by history or exam 
Calcinosis Skin calcinosis observed 
Proximal scleroderma Skin proximal scleroderma / extend at  or above wrist  
Sicca Skin sicca- xerophthalmia and xerostomia 
M
us
cl
e 
Myositis Myositis 
Myalgia Myalgia-subjective muscle acking involving proximal muscles 
Arthralgia Arthralgia 
Observed proximal weakness Any objective weakness in the proximal muscles 
History proximal weakness A subjective history of any proximal muscle weakness 
Muscular HAND SWELLING SPECIFIC At least one area swollen in a wrist, mcp, or pip joint 
Muscular HAND SWELLING GENERAL Muscular hand swelling 
Muscular HAND SWELLING HISTORY Swelling of the hand by history 
Muscular HAND SWELLING OBSERVED Swelling  of the hands observed 
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Jo
in
ts
 
Morning stiff Morning stifness lasting at least 1 hour before maximal improvement 
Join tender Joint tenderness observed 
Synovitys Synovitys 
Join swellling history History of joint swelling 
Join swellling obs Joint swelling observed 
Swelling joints > 3 Swelling of 3 or more joints (pip, mcp, wrist, elbow, knee, ankle and mtp) 
Symmetric swelling Symetric swelling observed 
Joints pain Joints pain 
Joints deformity Joints deformity 
L
ym
ph
 n
od
es
 
Any lymphadenopathy Any lymphadenopathy 
Lympnodes swelling Lympnodes swelling 
Neck lympnode Swelling Neck lympnode swellin 
Axila lympnode Swelling Axila lympnode swellin 
Groin lympnode Swelling Groin lympnode swellin 
Rheum nodule 
Observed rheumatoid nodule- subcutaneous nodules 
over bony prominences or extensor surfaces, or in 
juxtaarticular regions 
Gastro Gastric reflux 
Gastric reflux as diagnosed by patient symptoms of 
heartburn, acid reflux or chest pain and radiographic 
studies and/or endoscopy 
B
lo
od
 
Anemia Anemia 
Anemia hemolyti Hemolytic anemia 
Leukopenia Leukopenia 
Lymphopenia Lymphopenia, total lymphocyte count  < 1500/mm 
Thrombopenia Thrombocytopenia 
Thrombosis Thrombosis 
H
ea
rt
 
Pleuritis Convincing history of pleuritic pain or rubbing heard by a physician or evidence of pleural effusion 
Pericarditis Pericarditis: documented by ecg or rub or evidence of pericardial effusion 
PLEURITIS and/or PERICARDITIS Pleuritis and/or pericarditis: either or both of two above described  
Venous clot Venous clot  
Arterial clot Arterial clot 
Any clot Any clot 
Myocard infarction Myocardio infarction 
Valvular disease Valvular heart disease 
Valvular disease site Aortic, mitral, tricuspid, pulmonic 
Numb valvuar Based on the valvular disease type 
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Stroke Stroke 
Avascular necrosis Avascular necrosis 
Lu
ng
 
Pulmonary hyperten Pulmonary hypertension ≥40mmhg rvsp 
Pulmonaru vasc lesion Pulmonary vascular disease by biopsy or autopsy 
Pulmonary fibrosis Pulmonary fibrosis based on chest xray or ct scan 
Evidence of lung disease Lung disease define by phtn (clin-p1) + and/or pulmonary fibrosis (clin-p3) + 
K
id
ne
y 
Evidence of renal disease Renal disease define by acrrenal + and/or renal biopsy + 
Renal cell cast Renal cellular cast- red, hemoglobin, granular, tubular, or mixed 
Renal proteinuria Renal proteinuria- persistent > 0.5 grams/24hrs or > 3+ 
Renal hematuria Renal hematuria- > 5 rbc per high powered field 
Renal clot Reported renal clot 
Renal artery stenosis Reported renal arthery stenosis 
N
eu
ro
 
Seizure Seizure in the absence of offending drugs or known metabolic derangements 
Psychosis Psychosis in the absence of offending drugs or known metabolic derangements 
Neuropathy Any neuropathy 
Neuropsychiatric Neuropsychiatric 
Chorea Chorea 
L
ab
 te
st
s -
 M
et
ab
ol
ic
 P
an
el
 
Glucose Glucose normal range: 65-99 mg/dl 
Ureanitrogen (BUN) Urea nitrogen (bun)  normal range: 7-25 mg/ml 
Creatine Creatine  normal range: 0.5-1.4 mg/dl 
Serum creatine Serum creatine 
BUN/Creatine ratio  Bun/creatine ratio normal range: 6-25 calc 
Sodium  Sodium normal range: 135-146 mmol/l 
Potasium Potasium normal range: 3.5-5.3 mmol/l 
Chloride Chloride normal range: 98-110 mmol/l 
Carbon dioxide Carbon dioxide normal range: 21-33 mmol/l 
Calcium  Calcium normal range: 8.5-10.4 mg/dl 
Total protein  Total protein normal range: 6-8.3 g/dl 
Albumin  Albumin normal range: 3.7-5.1 g/dl 
Globulin  Globulin normal range: 2.2-4.2 g/dl 
Albumun/globulin  Albumun/globulin normal range: 0.8-2 calc 
Bilirubin Bilirubin normal range: 0.2-1.5 mg/dl 
Alkaline phosphatase Alkaline phosphatase normal range: 20-125 mg/dl 
Ast Ast normal range: 3-35 mg/dl 
Alt Alt normal range: 3-40 u/l 
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Creatine kinase Creatine kinase normal range: 0-165 u/l 
U
ri
na
ly
si
s 
Urine glucose Urine glucose normal range: 0 
Urine protein Urineprotein normal range: 0 
Urine WBC Urine wbc normal range: </= 5 
Urine RBC Urine rbc normal range: </= 5 
Urine squamos eplithelial cells Urine squamos eplithelial cells normal range: </= 5 
Urine bacteria Urine bacteria normal range: 0 
Hyaline cast Hyaline cast normal range: 0 
L
ab
 te
st
s -
 H
em
at
ol
og
y 
WBC count Wbc count normal range: 3.8-10.8 thous/mcl 
RBC count Rbc count normal range: 4.20-5.80 mill/mcl 
Hemoglobin Hemoglobin normal range: 13.2-17.1 g/dl 
Hematocrit Hematocrit normal range: 38.5-50% 
Mcv Mcv normal range: 80-100 fl 
Mch Mch normal range: 27-33 pg 
Mchc Mchc normal range: 32-36 g/dl 
Rdw Rdw normal range: 11-15% 
Platelet count Platelet count normal range: 140-400 thous/mcl 
Absolute neutrophils Absolute neutrophils normal range: 1500-7800 cells/mcl 
Absolute lymphocytes Absolute lymphocytes normal range: 850-3900 cells/mcl 
Absolute monocytes Absolute monocytes normal range: 200-950 cells/mcl 
Absolute eosinophils Absolute eosinophils normal range: 15-500 cells/mcl  
Absolute basophils Absolute basophils normal range: 0-200 cells/mhc 
Neutrophil % Neutrophil % normal range: 35-80% 
Lymphocyte % Lymphocyte % normal range: 18-44% 
Monocyte % Monocyte % normal range: 0-10% 
Eosinophyl % Eosinophyl % normal range: 0-3% 
Basophils % Basophils % normal range: 0-1% 
L
up
us
 S
pe
ci
fic
 la
b 
te
st
s 
Ana + Ana 
Anti-RNP + Anti-rnp at hemagglutination titer > 1:1600 
Anti-Sm Abs + Sm normal range: 0-20 
Anti-DNA Abs + Dsdna titer normal range: 5-9 iu/ml 
Dna elevated Elevated dna if ≥ 10 iu/ml 
FANA titer Fana titer  normal range: <320 
Fana_pattr Fana pattern. Homo , speckled  nucleolar, homo/speckled,  mixed , speckled/mixed, no-specific 
Ssa_result Ssa normal range: < 20 eu/ml 
Ssb_result Ssb normal range: < 20 eu/ml 
Scl_result Scl normal range: < 20 eu/ml 
Anti-phospho-lipid Abs + Anti-phospholipid abs + if > 10 gpl u/ml 
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Anti cardolipin antibody Anti cardolipin antibody if > 10 gpl u/ml 
Anticardiolipin igg LEVEL Anticardiolipin igg normal ranger: < 10 gpl u/ml 
Anticardiolipin igg + Anticardiolipin igg +  if > 10 gpl u/ml 
Anticardiolipin igm Level Anticardiolipin igm normal ranger: < 10 gpl u/ml 
Igm anticrd + Igm anticrd +  if > 10 gpl u/ml 
Anticardiolipin iga LEVEL Anticardiolipin iga normal ranger: < 10 gpl u/ml 
Iga anticrd+  Iga anticrd+ if > 10 gpl u/ml 
C3 complement level  C3 complement normal range: 90 – 180 mg/dl 
C3_low C3_low if < 90 mg/dl 
C4 complement level C4 complement normal range: 16 – 47 mg/dl 
C4_low C4_low if < 16 
Esr Esr nomal ramnge: < 10 mg/dl 
Esr_elevated Esr_elevated if >10 mg/dl 
C reactive protein C reactive protein nomal range: 1.0 mg/dl 
Crp_elevated Crp_elevated fi . 1.0 mg/dl 
RF latex Titer Rf latex titer normal range: 14 iu/ml 
RF ELISA igm Titer Rf elisa igm titer normal range: < 20 iu/ml 
RF ELISA igg Titer Rf elisa igg titer normal range: < 20 iu/ml 
Cpk level Cpk normal range: < 165 u/l 
CPK elevated Cpkeleavted: > 165 u/l 
E
xp
er
im
en
ta
l L
ab
 te
st
 
Baff Baff normal cytokine level < 1.19 ng/ml  (based on healthy group average + sd of healthy group) 
Baffr Baffr normal cytokine level < 0.09 ng/ml  (based on healthy group average + sd of healthy group) 
Taci Taci normal cytokine level < 0.02 ng/ml  (based on healthy group average + sd of healthy group)  
Bcma Bcma normal cytokine level < 1.64 ng/ml  (based on healthy group average + sd of healthy group) 
Ifng Ifng normal cytokine level < 13.13 pg/ml  (based on healthy group average + sd of healthy group) 
Tnfa Tnfa normal cytokine level < 7.58 pg/ml  (based on healthy group average + sd of healthy group) 
Scd40l Scd40l normal cytokine level < 1959.30 pg/ml  (based on healthy group average + sd of healthy group) 
Il12p40 Il12p40 normal cytokine level < 61.68 pg/ml  (based on healthy group average + sd of healthy group) 
Il12p70 Il12p70 normal cytokine level < 18.77 pg/ml  (based on healthy group average + sd of healthy group) 
Il23 Il23 normal cytokine level < 348.34 pg/ml  (based on healthy group average + sd of healthy group) 
Il17a Il17a normal cytokine level < 3.88 pg/ml (based on healthy group average + sd of healthy group) 
Il17af Il17af normal cytokine level < 19.40  pg/ml  (based on healthy group average + sd of healthy group) 
Il17f Il17f normal cytokine level < 38.00 pg/ml  (based on healthy group average + sd of healthy group) 
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Il21 Il21 normal cytokine level < 13.5 pg/ml  (based on healthy group average + sd of healthy group) 
Il22 Il22 normal cytokine level < 31 pg/ml  (based on healthy group average + sd of healthy group) 
Il33 Il33 normal cytokine level < 12.3 pg/ml  (based on healthy group average + sd of healthy group) 
E-selectin Eselectin normal cytokine level < 23.63 ng/ml  (based on healthy group average + sd of healthy group) 
Ngal Ngal normal cytokine level < 79.10  ng/ml  (based on healthy group average + sd of healthy group) 
Igm anti-U1A (196-203) titer P1-igm average normal range: 0-100  
Igm anti-sme (63-70) titer P2-igm average normal range: 0-100  
Igm anti-smf (46-53) titer P3-igm average normal range: 0-100 
Igm anti-U1C (90-97) titer P4-igm average normal range: 0-100 
Igm anti-U1-70K (337-344) titer P5-igm average normal range: 0-100 
Igm anti-smb (83-90) titer P6-igm average normal range: 0-100 
Igm anti-smg (1-8) titer P7-igm average normal range: 0-100 
Igm anti-smd3 (20-27) titer P8-igm average normal range: 0-100 
Igm anti-smf (77-84) titer P9-igm average normal range: 0-100 
Igm anti-U1A (112-119) titer P10-igm average normal range: 0-100 
Igm anti-smd2 (14-21) titer P11-igm average normal range: 0-100 
Igm anti-smd1 (22-29) titer P12-igm average normal range: 0-100 
Igm anti-U1A (178-185) titer P13-igm average normal range: 0-100 
Igm anti-U1-70K (325-332) titer P14-igm average normal range: 0-100 
Igm anti-U1C (66-73) titer P15-igm average normal range: 0-100 
ELISA anti-snrnp Based on healthy group average + sd of healthy group 
Immunoblot anti-70KD Based on healthy group average + sd of healthy group 
Immunoblot anti-Sm Based on healthy group average + sd of healthy group 
Immunoblot anti-U1-A Based on healthy group average + sd of healthy group 
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APPENDIX 4 
Biological system Variable 
C
LI
N
IC
A
L
 M
A
N
IF
ES
TA
TI
O
N
S 
SKIN 
Telangiectasia  
Nasal ulcers 
Oral ulcers 
Hist hand swelling 
Obs hand swelling 
Sclerodactyly  
Pitting  
Alopecia  
Rash  
Photosensitivity 
Discoid rash 
Raynaud's 
Calcinosis  
Prox sclerodema 
Sicca 
MUSCLE 
Myositis 
Myalgia 
Arthralgia 
Hist prox muscle weakness 
 Obs prox muscle weakness  
Hist hand swelling  
Obs hand swelling  
Low extremety swelling 
Facial swelling 
JOINTS 
Morning stiff 
Tender  
Synovitys 
Hist swelling 
Obs swelling  
Swelling (>3) 
Symmetric sweeling  
Pain 
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Deformity 
LYMPH 
NODES 
Any lymphadenopathy 
Swelling 
Neck  swelling 
Axila swelling 
Groin  swelling 
Rheumatoid nodule 
GASTRO Gastric reflux 
BLOOD 
Anemia 
Hemolytic anemia 
Leukopenia 
Lymphopenia 
Thrombopenia 
Thrombosis 
HEART 
Pericarditis 
Pleuritis 
Pericarditis/pleuritis 
Any clot 
Venous clot 
Valvular disease 
Avascular necrosis 
Myocardial infarction 
Stroke 
LUNG 
Hypertension 
Vascular lesions 
Fibrosis 
Lung disease 
KIDNEY 
Proteinuria 
Hematuria 
Clot 
Artherial stenosis 
Cell cast 
Renal disease 
NERVOUS 
Neuropathy 
Psychosis 
Chorea 
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APPENDIX 4, continuation 
 
Lab tests Variable 
LA
BO
R
A
TO
R
Y
 T
ES
TS
 
U
R
IN
A
L
Y
SI
S 
Glucose + 
Protein + 
Wbc + 
Rbc + 
Squamos eplithelial cells + 
Hyaline cast + 
TR
A
D
IT
IO
N
A
L 
FO
R
 L
U
PU
S 
Sm level 
Sm + 
Dsdna titer 
Dna + 
DNA elevated 
FANA titer 
Fana + 
Ssa + 
C3 level 
C3 low 
C4 level 
C4 low 
Esr 
ESR elevated 
Crp 
CRP elevated 
Igm-RF ELISA titer 
Igm-RF + 
Igg-RF ELISA titer 
Igg-RF + 
CPK level 
CPK elevated 
EXPERIMENTAL 
Il17a 
Igm-U1A ELISA (112-119) 
Igm-U1A ELISA (196-203) 
Igm-smd2 ELISA (14-21) 
Igm-smd2 ELISA (14-21) 
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